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ABSTRACT 
OBJECT ORIENTED PARTITIONING FOR A MEDICAL VOCABULARY 
BASED ON SEMANTIC NETWORK 
by 
Mansnimar Singh 
Computers have become ubiquitous and indispensable part of everyday life both 
for personal use and in the workplace. Medicine is one of the few domains that. has not 
fully adopted computerization. One impediment to this emanates from a communication 
gap between the computer science professional and the medical professional. Besides, 
medical terminology is full of synonyms and medical professionals use them according to 
their personal preferences. This lack of common terminology has prevented sharing of 
knowledge and automating data processing, resulting in the healthcare information 
explosion. 
Semantic network models have been developed to represent medical concepts and 
to provide a common repository of medical terms. These networks are huge collections 
of terms and deal with the concepts individually. The semantic models, however, have 
not resolved management and comprehension difficulties associated with large number of 
terms and their complex semantics. 
Object-Oriented modeling, as demonstrated in this thesis, provides a mature 
technology to model complex concepts for a computerized medical vocabulary. Object 
class abstraction, that represents objects in the same context, promises to solve the 
comprehension and management problems. Such a vocabulary would facilitate exchange 
of information, data processing and building decision support systems. 
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CHAPTER 1 
INTRODUCTION 
1.1 Objective 
Large semantic networks like medical vocabularies are difficult to comprehend and 
maintain because of the huge number of concepts and the complex semantics associated 
with them. The objective of this thesis is to analyze the concepts in a semantic network 
based medical vocabulary and to partition them into logical units. These logical groups 
can then be represented by object class hierarchies. The class model reduces the number 
of concepts and semantic relationships in the network and facilitates comprehension and 
management of medical information. The source of the concepts for this model is the 
Columbia Presbyterian Medical Center's Medical Entities Dictionary (MED). 
1.2 Background Information 
The origin of modern medicine can be traced to ancient Greece where Hippocrates of Cos 
laid its foundation. Medical science has expanded and become more sophisticated as 
knowledge has accumulated over the millennia. This has led to the evolution of a highly 
complex terminology. In the recent decades medicine has advanced at a meteoric pace 
and so has the medical terminology. 
In order to share knowledge, information has to be distributed and exchanged 
between different organizations and information systems. This can only be accomplished 
if a common terminology is available to facilitate the integration process. However, 
conventional data models do not fully capture the essence of medical concepts. The 
problem has been compounded by the need for terminology concepts to be pooled from 
various sources and interpreted by computer systems. 
There is therefore a pressing need to build a computerized medical vocabulary 
that would provide a common language for conversation between organizations or 
computer systems and accommodate the perspectives of all its users. 
CHAPTER 2 
COMPREHENSION DIFFICULTIES OF MEDICAL TERMINOLOGY 
A terminology is a set of words or phrases that are used to describe the concepts in a 
domain. The basic domains of medicine that are required to be represented in any 
medical vocabulary are the diseases, their diagnostic procedures and treatment modalities. 
The main factors that lead to difficulties in understanding medical terminology are the 
number of terms and their semantics. 
2.1 Size of the Medical Vocabulary 
Medical terminology has continued to grow as knowledge has accumulated over the 
centuries. In other vocabularies some terms become obsolete as the domain evolves and 
new terms are coined. But in medicine the domains have expanded without making some 
terms obsolete. This is due to the fact that humans have continued to suffer from the 
same maladies and only one major disease, Smallpox, has been eradicated from the 
world. The major form of Diabetes (Diabetes Mellitus characterized by excessive urine 
which is sweet) had been discovered centuries ago and continues to be an important cause 
of morbidity and mortality. 
A number of human factors have led to the rapid expansion of the medical 
vocabulary. The average human life span has increased dramatically in the last few 
decades and this has led to the recognition of diseases associated with old age like 
Alzheimer's Disease, Paget's Disease and numerous malignancies [2, 14]. The rapid 
growth of human population and tourism has led people to venture into previously 
uninhabited terrain with its own microcosm. This has led to the discovery of new 
pathogens (disease causing agents) whose primary hosts are immune but now have a new 
unprotected human host at their disposal. 
Advancements in technology have led to the identification of many diseases and 
also contributed to new conditions. Industrialization has added new classes of toxic and 
disease causing substances that are responsible for many occupational diseases like Coal 
Miners Lung or Asbestosis. Introduction of compact cars led to cases of Window Slash 
Fracture occurring when a person with his elbow protruding out of the carwindow was 
sideswiped by a passing car. Computers themselves have their share of blame and 
Repeated Traumatic Injury to the wrist has become a well recognized syndrome among 
computer professionals engaged in continuous typing on keyboards. 
Even sports, due to extreme stress placed on body parts that were not conditioned 
for these forces, has led to new medical afflictions. Golfer's elbow and Tennis Elbow 
result from excessive strain on certain tendons and ligaments [1, 2]. In fact, sports 
medicine has become a highly specialized field in its own right. 
Another culprit responsible for comprehension difficulties in medical terminology 
is the lack of standardized rules for coining new terms. In the absence of accepted 
taxonomy guidelines, there are many sources of inspiration for coining new terms. Some 
concepts bear the name of the person who discovered the condition (Crigler-Najjar 
Syndrome describes a deficiency of an enzyme in bilirubin metabolism) while others 
describe the place of discovery (Rocky Mountain Spotted Fever). Some concepts 
describe the organ and pathological manifestation of the disease (Gastritis describes the 
inflammation of the stomach) and some have roots in mythology and religion (Saint 
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Vitus' dance describes the sudden, aimless, irregular movements in. Rheumatic Heart 
Disease) [2, 12, 14]. These diverse naming conventions make new terms difficult to 
interpret. To add to this confusion are the abundant synonyms that arise because different 
people encountered the diseases independently and named it according to their 
interpretation. Furthermore, many conditions were named after the same discoverer so 
these names need additional qualifications to avoid confusion. For example, Paget's 
disease can occur in bones or breast but the etiology and pathology of both are very 
different [12, 14]. 
The need to treat all the diseases has led to an explosive growth in 
pharmacological preparations. In the pharmacy domain once again there are few rules for 
naming compounds and pandemonium reigns. Many names are based on the chemical 
family of the constituents (a.minoglycoside refers to amino sugars linked by glycoside 
linkage to hexose nucleus) while some refer to the source of the chemical in the human 
body (adrenocorticosteroids are steroids produced by adrenal glands). Some terms are 
abbreviated names for the chemicals and this adds confusion to the existing disarray in 
the vocabulary (aspirin is the commonly used short name for acetylsalicylate) [9]. 
Medical diagnostic and therapeutic procedures have also added their jargon to the 
medical terminology. Diagnostic procedures may detect chemicals (like Glucose) or 
evaluate immunologic status (like Human Leukocyte Antigen for transplant organ 
matching and antibody titre for various diseases) or process information using electronic 
devices (like Electrocardiogram, Computer Aided Tomography scan, Positron Emission 
Tomography, Nuclear Magnetic Resonance, Echocardiography). Therapeutic procedures 
(like valvulotomy to repair narrowed heart valves or Percutaneous Tranluminal Coronary 
Angioplasty for opening clogged heart arteries in myocardial ischemia) have further 
expanded the terminology [14]. 
2.2 Multiple Views and Relationships among Medical Concepts 
Another dimension contributing to the comprehension difficulties is the semantics of the 
concepts. A medical vocabulary is not just a collection of terms from the medical 
domains but must be able to reflect multiple perspectives of medical professionals from 
different specialties. A clinician would like to obtain the result of the blood glucose test 
for a patient without worrying about the method while a lab technician would be more 
concerned with which tests measure glucose and what specimen is used for those tests. 
This requires multiple views of concepts to satisfy users from different domains [3, 6]. 
Besides the multiple views, each concept may relate to many other concepts. Lab 
tests are related to the type of specimen used and the substance they measure while 
disease concepts are associated with the afflicted site, the etiology and the diagnostic tests 
for the condition. Thus concepts with multiple views and relationships make medical 
terminology even more complex and difficult to model. 
2.3 Current Computerized Medical Vocabularies 
There have been attempts to create computerized medical vocabularies using semantic 
networks. The Unified Medical Language System (UMLS), that includes a medical 
knowledge base with a semantic network structure, has attempted to provide a common 
pool of terms. The purpose of the UMLS is to facilitate integration of electronic 
biomedical information from a variety of sources. This will help in better linking of 
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patient data to other databases making it useful for research and building decision support 
systems [4]. 
Another successful vocabulary is the MED that consists of concepts used at 
Columbia Presbyterian Medical Center (CPMC). CPMC has used this vocabulary to 
successfully integrate information from its major sources of medical data: patient records, 
labs and pharmacy. It has helped solve inter-departmental communication problems 
within CPMC [3]. 
However, both these models consider concepts at the term level and therefore 
suffer from comprehension problems because of their huge size and complex structure. 
2.4 Complexity of Semantic Networks 
The effort required to understand a semantic network depends on the number of concepts 
and on the inter-relationships between the concepts. In order to quantify the 
comprehension difficulties of a semantic network schema, its size is defined as the 
number of concepts and its complexity, c, is defined as the ratio of the number of 
relationships between the concepts to the number of concepts. For two networks of equal 
size i.e., with same number of concepts, a more complex network, with its greater number 
of relationships per concept, is more difficult to comprehend [8, 11]. 
CHAPTER 3 
MODELING MEDICAL CONCEPTS 
Medical concepts are difficult to represent with conventional data models. For modeling 
these concepts some sort of abstraction is needed that simplifies the concepts by focusing 
on the essential features and ignoring the non-essential ones. A good representation 
model would be one that captures all the features of the medical concepts and their 
relationships to other concepts. The model should also be suitable for all users of 
medical information. In this chapter we consider two models for representing medical 
concepts. 
3.1 Semantic Network Model 
One way to express the concepts in a medical vocabulary is by a semantic network 
model. In this network each concept is represented as a node. For a complete 
representation of the term and its semantics, each concept requires at least two types of 
properties: 
1. Attributes - the properties of the concept that apply to the concept itself, and 
2. Relationships - those that relate the concept to other concepts and capture its 
semantics. 
3.1.1 Medical Entities Dictionary 
The Medical Entities Dictionary (MED), developed by Columbia Presbyterian Medical 
Center (CPMC), is one such vocabulary based on a semantic network model. CPMC has 
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placed terms from its hospital systems (laboratory, electrocardiography, medical records 
coding and pharmacy) in the MED to facilitate data storage and exchange [3]. 
The CPMC has two data repositories: 
I. 	 Medical Entity Dictionary (MED) which is a collection of terms that serves as a 
common reference for users from different departments, and 
2. Clinical Data Base (CDB) that stores patient's clinical information by using the 
codes from the MED. 
The MED considers each concept to be a term that is uniquely identified by its 
MED-CODE. The MED-CODEs in a patient's record capture the clinical state of the 
patient by specifying his condition (from disease MED-CODEs), tests and their results 
(from lab and ECG MED-CODEs) and therapy being administered (from pharmacy 
domain MED-CODEs) [6, 7]. The MED-CODEs are also used while querying the patient 
data in the CDB for specific conditions, tests and treatments. 
MED Concepts 
The MED semantic network represents medical concepts as nodes with links between 
them. Each concept node in the MED graph can be viewed as a frame with properties 
that describe the characteristics of the concept. The MED uses the properties of the term 
to store information that describes the entities themselves (i.e., local information) in 
attributes and those describing how the entities are related to other entities in 
relationships. Any information that relates to other concepts and is not intrinsic to the 
concept is not stored locally because this leads to redundancy [3, 6, 7]. For example, in 
the pharmacy domain a chemical compound may be an ingredient of many preparations. 
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In an ointment form it may exist in a particular strength and in a tablet form as a different 
strength. If all the information pertaining to the chemical constituent is stored in the 
nodes of the preparations instead of relating the preparation to its chemical constituent 
node, then each preparation would have to store this information individually leading to 
redundancy and maintenance difficulties. The use of relationships allows multiple 
pharmacological preparations to refer to their constituent concepts and helps in 
maintaining the integrity of the information. 
MED Relationships and Attributes 
The root of the MED network is the concept Medical Entity. The IS-A hierarchy which 
is introduced by Medical Entity's SUBCLASS-OF (IS-A) relationship provides the 
inheritance path for properties of all the concepts. This hierarchy also allows multiple 
inheritance to accommodate multiple views for users from different medical 
specializations. 
The IS-A hierarchy of the MED is very similar to that of the CYC project [15]. 
The concept Medical Entity, as the root node of the hierarchy, represents all the medical 
concepts in the most general form. All other concepts are immediate descendants of at 
least one other node. Each concept may have several parents but the IS-A relationships 
between the child and it's ancestors are acyclic, making the hierarchy a Directed Acyclic 
Graph (DAG) [3]. 
Each MED concept is characterized by its properties. A property is introduced at 
a single node in the graph and is inherited by all it's descendant nodes. There are a total 
of 150 properties in the MED that are used to define all the possible features of medical 
concepts. These properties are of two types: 
1. Attributes hold primitive values like the NAME of the concept, its MED-CODE, 
its code in other medical vocabularies like UMLS-CODE, its SYNONYMS etc 
2. Relationships point to other concepts and specify how the concepts relate to each 
other in the network. For example, the SUBCLASS-OF relationships specify the 
parents of the concept and the PHARMACEUTIC-COMPONENT relationship 
specifies the chemical ingredient(s) of the pharmacological preparation. 
The domain of a concept consists of all descendants of a concept in the IS-A 
hierarchy because the descendants inherit the properties of it's ancestors and the ancestor 
concept represents the descendants in a generic form [3]. For example, the children of the 
concept Antibiotic Preparations include chemical families like the concepts 
Aminoglycoside Preparations, Penicillin Preparations and Cephalosporin Preparations. 
The concept Antibiotic Preparations represents these chemical families in a generic form 
without associating them with any specific chemical family. Within each chemical 
family are a number of specific compounds that are modifications of the family structure. 
The family root concept represents the individual structures in a generic form. For 
example, the concept Aminoglycoside Preparations generically represents its descendants 
like the concepts Neomycin Preparations and Kanamycin Preparations each of which 
share common family structure and properties but differ in specific functional groups that 
account for variations in their actions and indications for clinical usage. 
Each relationship can be assigned values from a specific domain only [3]. In the 
pharmacy domain the relationship PHARMACEUTIC-COMPONENT (113), introduced 
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by the concept Pharmacy Items (Drugs and Nondrugs), is used to refer to the chemicals 
that form that drug. These chemicals are in the domain that is the inverse of relationship 
113 i.e., PHARMACEUTIC-COMPONENT-OF (114) introduced by the concept 
Chemicals that relates individual chemical ingredients to the pharmacological 
preparations. This restriction prevents disastrous assignments like a drug concept having 
a disease concept as its constituent rather than a chemical. 
Each term in the IS-A hierarchy has all the properties introduced by its ancestors. 
Since a term can be viewed as a specialization of more than one parent concept, the 
SUBCLASS-OF relationship may be multi-valued leading to multiple inheritance of 
properties. This allows the concepts to capture the features of the different domain 
perspectives [6, 7]. For example, the concept Neomycin Preparations inherits its basic 
family chemical properties from the parent concept Aminoglycoside Preparations and its 
DEA category from the Drug Enforcement Agency (DEA) Class 0 Drugs without Abuse 
Potential concept parent. Similarly other non-hierarchical relationships may also be 
multi-valued. Pharmacological preparations may have multiple ingredients and therefore 
are related to these components by multiple PHARMACEUTIC-COMPONENT 
relationships. This array of multi-valued relationships makes the vocabulary very 
complex but is essential to adequately capture the semantics of the concept and thus 
provide a common pool of terms to professionals from different medical disciplines. 
3.1.2 Format of the MED Files 
The information in the MED is held in two files, the slot file and the flat file. 
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Slot file 
The slot file consists of tuples of seven comma separated values. Each tuple describes a 
slot and there are 150 slots in the MED's slot file. The format of the entries in each tuple 
is as follows: 
1. Slot ID that is an integer 
2. Unique slot name that is a string 
3. MED CODE of concept where the slot is introduced 
4. Directionality of link (for graphical display). The possible values are 
• no directionality, as the attribute is a literal 
• points UP to "parent" entity via the relationship 
• points DOWN to "child" entity via the relationship 
5. Propagate attribute values to the descendants 
• NO 
• YES 
6. ID of inverse relationship slot number 
• NULL field => no reciprocal relationship possible 
• positive integer => ID of reciprocal relationship 
• negative integer => reciprocal relationship possible but not defined 
(empty for attributes) 
7. The data type for an attribute that can be numeric or string but only numeric for a 
relationship. Null field indicates that the value stored is a relationship - a link to a 
medical entity. 
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Flat File 
The flat file contains triplets that describe the properties of each concept. The format of 
the tuples is: 
Med-code of concept 
2. Slot ID 
3. Med-code of the concept related to (1 ) by slot (2) in case it is a relationship, 
otherwise it is the value of the attribute described by the slot. 
The properties for each concept may be multi-valued. Then they are represented 
by multiple tuples, one for each distinct value for that property. The slot file and the flat 
file entries for the sub-net being analyzed are provided in the appendix. 
3.2 Object-Oriented Model 
Object-Oriented models are organized around real world concepts. These concepts are 
represented by objects, which combine both the data structure and the behavior in a single 
entity. The essence of Object-Oriented modeling is the identification and organization of 
application-domain concepts and their classification into class hierarchies [13]. 
3.2.1 Object-Oriented Model for the MED 
This thesis deals with the development of the Object Model for a medical vocabulary. 
The source of the concepts for this model is the CPMC MED. The following sub-
sections describe the components of the Object Model. 
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3.2.1.1 Objects: Object-Oriented modeling stresses specifying what an object is rather 
than how it is used. Each object is a unit of data that is encapsulated into the object. As 
the system requirements evolve, the features of a well defined object are much more 
stable than the ways it is used [13]. 
In the real world, all objects have an identity and are distinguishable by their 
inherent. existence and not by their descriptive properties [13]. Therefore in the real 
world there may be multiple instances of the same type. For example, two patients 
suffering from the same type of pneumonia (Pneumococcal pneumonia) may differ in the 
extent of lung involvement (one lobe vs. multiple lobes) as evident in. the chest X-Ray 
and therefore be prescribed different drug regimes (oral Ampicillin 250 mg Capsule every 
6 hours vs. intravenous Ampicillin 500 mg every 6 hours). The improvements in the 
patient's status might be reflected in their X-Rays and may lead to changes in the drug 
regime. 
In the MED, on the other hand, the concepts are defined by their properties and 
therefore no two concepts can have the same properties with the same assigned values. 
We need only one term for a particular disease (Pneumococcal Pneumonia) or drug 
(Ampicillin 500 mg Capsule) or test (Chest X-Ray) and no user modifies it. Since the 
terms are used only as reference objects and are not modified by the applications, they 
can be shared and there is no need for separate copies for each application. If the terms 
differ only in name, with all properties having identical values, then they are considered 
to be synonyms unless specified by a domain expert as distinct [3]. 
16 
Attributes of the Objects 
An attribute is a data value held by the objects in a class. Each attribute has a value for 
each object instance and this is a pure data value. 
The attributes of the objects in the Object Model are the mapping of attributes of 
the MED concepts. 
Relationships of the Objects 
Relationships are the means for establishing links among objects and classes. 
Relationships in the MED are unidirectional because the reverse relationship always 
expresses different semantics. For example, a chemical compound may be 
PHARMACEUTIC-COMPONENT-OF a pharmacological preparation but the inverse 
relationship, PHARMACEUTIC-COMPONENT, implies that the preparation contains 
the chemical identified in the relationship. 
In the MED a relationship is defined by a tuple in the flat file. The MED 
relationships are mapped to obtain the relationships for objects in the Object Model. 
Multiplicity of Relationships 
Multiplicity specifies how many instances of one class may relate to a single instance of 
an associated class. All the relationships in the MED are potentially multi-valued. This 
is helpful for the SUBCLASS-OF relationships in providing multiple views of the 
concepts in a IS-A hierarchy. For example, in the pharmacy domain a drug may be 
viewed by its functional classification (or actions), its DEA or its allergic categorization. 
Besides the IS-A relationship, other relationships can also be multi-valued and this allows 
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a concept to be associated with many other concepts. For example, a pharmacological 
preparation may be composed of many chemicals and a lab test panel may consist of 
many tests. 
3.2.1.2 Classes: A class is an abstraction that describes the common properties of the 
objects. These classes are built around contexts that are shared by the concepts. The 
objects in a class therefore have the same data structure and behavior. Partitioning the 
concepts in a system like MED, will help in identifying the contexts for building object 
classes. This will provide a macro (class) view with reduced complexity and a micro 
(instance) view if detailed information is required. 
The contexts in a system are not always easy to determine especially in medicine 
where concepts occur under multiple classifications to accommodate experts from 
differing specializations. At the present time, the computer systems are not sophisticated 
enough to determine the contexts and for a medical vocabulary there is a need. for a 
domain expert to identify the contexts. In the pharmacy domain, the chemical 
constituents are the primary and determining features of drugs. For example, the 
concepts Neomycin Preparations and Kanamycin Preparations are SUBCLASS-OF the 
concept Aminoglycoside Preparations. The aminoglycoside family represents these 
preparations in a generic form by a class abstraction. 
3.2.2 Advantages of an Object-Oriented Model for Medical Vocabulary 
An Object Model will classify concepts into classes that represent concepts in the same 
context. 13y representing many individual concepts by a far smaller number of contexts, 
the object class abstraction reduces the volume of information presented to the user and 
thereby enhances comprehension. The class model would provide a macro view of the 
domain in terms of classes representing objects in the same context and a micro view in 
terms of concepts within each class. Thus the Object Model can help in creating a 
successful computerized medical vocabulary. 
In chapter 6 we will apply object-oriented modeling techniques to a well-defined 
sub-schema of the MED medical vocabulary. 
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CHAPTER 4 
INTRODUCTION TO PHARMACOLOGY 
In our analysis of a MED sub-net we will make extensive use of the knowledge of a 
medical expert. In order to get a window at the kind of reasoning performed by this 
expert, we need to give a comprehensive introduction to the fundamental principles of 
pharmacology and the basic pharmacological concepts that appear in the MED sub-
schema. 
4.1 General Principles of Pharmacology 
One of the major domains of medicine is the field of pharmacology that studies 
substances that interact with living organisms. These interactions may be clue to [9]: 
1. Physical properties of substances. For example, Glycerol has hygroscopic (water 
retaining) properties and is therefore used in many lotions as an emollient, or 
2. Chemical interactions especially by binding to regulatory molecules. In most 
cases certain pathological bio-processes are responsible for the manifestations of a 
disease. Medicinal substances may activate or inhibit biological chemical 
reactions leading to resolution of the pathological process. For example, fever is 
usually produced by certain prostaglandins that act on the thermoregulatory center 
in the hypothalamus. Aspirin inhibits the synthesis of these prostaglandins and is 
therefore used as an anti-pyretic agent. 
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4.1.1 Drug Body Interaction 
The interactions between a drug and the body are of two types [5, 9] : 
1. Pharmacodynamics - the actions of the drug on the body. These properties 
determine the actions of the drugs and therefore the functional classification of the 
drugs. 
2. Pharmacokinetics - the action of the body on the drug. These properties govern 
the absorption, distribution and elimination of the drugs. These aspects are 
important for determining whether and how a drug can be used in a particular 
patient: 
a) Absorption of a drug determines the best route for its administration. 
Aminoglycosides cannot be absorbed from the gastrointestinal tract (GIT) 
and therefore are injected into the body rather than being administered orally. 
Due to the same reason aminoglycosides are used for intestinal antisepsis 
before bowel surgery to reduce the chance of postsurgical infection. On the 
other hand, adrenal steroids are absorbed freely from all surfaces and mucus 
membranes and hence even topical application may lead to systemic side 
effects that are undesirable. 
b) Distribution of the drug determines whether it reaches the diseased site. For 
example, aminoglycoside cannot cross the blood brain barrier (a biological 
barrier that selectively shields the brain from chemicals in the blood) because 
of its chemical nature and therefore if it is required for treating brain infection, 
it has to be introduced directly into the meninges covering the brain or the 
ventricles. 
c) Drug elimination is important because it determines the dosage schedules and 
whether the patient can tolerate the drug. If a drug is eliminated by kidneys 
(like aminoglycosides), it would be avoided if renal function is compromised 
or at least the dose would be reduced to avoid accumulation of drugs to toxic 
levels. Long acting drugs are eliminated slowly and require less frequent 
administration. 
4.1.2 General Properties of Drugs 
In general, a drug is any substance that brings about a change in biologic function. In 
most cases, the drug molecule interacts with specific molecules, called receptors, in the 
biologic system that regulates a physiologic process. In order to interact chemically with 
its receptor, a drug molecule must have the appropriate properties so it can reach its site 
of action and be recognized by the receptors [9]. These properties depend on the 
chemical structure of the drug. Some important features of the drugs are: 
I . 	 Molecular Size: Most of the drugs have molecular weights between 100 and 
1000. In order to have specific actions, a drug molecule must be sufficiently 
unique in shape and charge to bind to only one type of receptor and avoid binding 
to other receptors. The lower size limit is dictated by the need for a drug 
molecule to be recognized as distinct from other molecules. Also the drug may 
not be administered directly at the site of action and in that case must be able to 
reach the desired site. This limits the size of the drugs as very large molecules are 
difficult to transport between body compartments. 
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2. Drug Reactivity: Drugs interact with receptors by means of chemical forces or 
bonds. There are many types of bonds between the drug and the receptor but the 
weaker ones lead to more specific interaction with receptors. This is because 
weak bonds require a precise fit of the drug to its receptor. Only a few receptor 
types are likely to provide such a precise fit for a particular drug molecule having 
a specific chemical structure. 
3. Drug Shape: The shape of a drug molecule must permit binding to its receptor 
site. In the optimal case, the drug's shape is complementary to that of the receptor 
site. Some of these compounds may even have the same chemical structure but 
still differ in 3-D shape (phenomenon of chirality or sterioisomerism). The chiral 
pairs which have the same chemical structure but different 3-D orientation are 
called enantiomeric pairs. One of these enantiomers will be much more effective, 
have different side effects and duration of action reflecting a better fit for the 
receptor molecule. 
So the major features of drugs depend on the family chemical structure that 
determines the size and shape of the drug molecule. Minor variations in the specific side 
chain chemical group and the 3-D orientation of the molecules further give the drug its 
specific properties within that chemical family. 
4.2 Pharmacology of Drug Concepts in the Sub-net 
4.2.1 Adrenocorticosteroids 
The natural adrenocortical hormones are steroid molecules produced and released by the 
adrenal cortex. 
23 
Chemical Structure 
The basic family structure of the steroid hormones consists of the 
cyclopentenoperhydrophenanthrane or pregnane nucleus [5, 9, 12]. The adrenal cortex 
synthesizes two classes of steroids: 
1. the corticosteroids (glucocorticoids with main effect on intermediate metabolism 
and inflammation and mineralocorticoids with salt retaining properties) having 21 
carbon atoms, and 
2. the androgens having 19 carbon atoms. 
Figure 1 Structure of Adrenocorticosteroids (1-Hydrocortisone 
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Structure-Activity Relationship 
Modifications in the chemical structure of a corticosteroid may effect its affinity for 
glucocorticoid and mineralocorticoid receptors, its duration of action and transport to 
various sites. The following alterations of the pregnane nucleus demonstrate the 
importance of the chemical structure of glucocorticoids [5]: 
1. Ring A: A 4,5 double bond and the 3-ketone are both necessary for typical 
adrenocorticosteroid activity. Introduction of a 1,2 double bond, as in prednisone 
or prednisolone, enhances glucocorticoid potency more than the 
mineralocorticoid. In addition, prednisolone is metabolized slowly and therefore 
has a prolonged effects on the body. 
2. Ring B: 6∞-Methylation in cortisol increases glucocorticoid effects and 
fluorination in the 9∞ position enhances all biological activities of the 
corticosteroids. 
3. Ring C: The presence of an oxygen function at C-1 1 is indispensable for 
significant anti-inflammatory and carbohydrate-regulating ability. 
4. Ring D: 16-Methylation or hydroxylation selectively eliminates the 
mineralocorticoid effect of the drug. 
These variations are useful in creating drugs for specific purposes. A 
corticosteroid with minimal mineralocorticoid effect would be less likely to cause 
hypertension as its side effect. A long acting preparation like prednisolone would have 
simpler dosage schedules for patients and would improve compliance. A short acting 
formulation like hydrocortisone, on the other hand, would be useful in emergencies where 
its effect is brief and its dose can be easily titrated to achieve the precise response. 
Mechanism of Action 
GI ucocorticoids diffuse or are transported through cell membrane and enter the cell where 
they bind to the cytoplasmic glucocorticoid receptor-heat-shock protein complex. The 
heat shock protein is released and the hormone receptor complex is then transported into 
the nucleus, where it interacts with glucocorticoid response elements (GREs) on various 
genes and other regulatory proteins (which may be cell specific). This interaction may 
stimulate or inhibit the expression of the gene resulting in the manifestations of its effects 
[9]. 
Pharmucokinetics 
The adrenal steroids are absorbed from all surfaces because the cell membranes 
themselves have a steroid structure that allows these chemicals to diffuse easily. They 
are inactivated by reduction of the 4,5 double bond that occurs in the liver as well as 
extrahepatic sites [5]. 
4.2.1.1 Hydrocortisone: Hydrocortisone is a glucocorticoid and shares all the features 
discussed above. 
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4.2.2 Aminoglycosides 
Aminoglycosides are a group of bactericidal drugs originally obtained from various 
Streptomyces species. They share chemical, antimicrobial, pharmacologic, and toxic 
characteristics. Some of the members of this family includes streptomycin, neomycin, 
kana.mycin, amikacin, gentamicin, tobramycin, sisomicin and netilimicin. 
Chemical Structure 
Aminoglycosides have a hexose nucleus, either streptidine (in streptomycin) or 
deoxystreptamine (in other aminoglycosides), to which amino sugars are attached by 
glycosidic linkages. Each drug is characterized by the number and kind of amino sugars 
[5, 9]. 
Mechanism of Action 
Aminoglycosides are bactericidal for susceptible organisms due to inhibition of protein 
synthesis. An aminoglycoside enters the bacterial cell and binds to receptors on the 30S 
subunit of the bacterial ribosome. Ribosomal protein synthesis is then inhibited and the 
bacteria is killed [9]. 
Pharmacokinetics 
Aminoglycosides are absorbed poorly from the intact gastrointestinal tract. They can be 
given by intramuscular or occasionally intravenous injection. Being highly polar 
compounds, unlike glucocorticoids, aminoglycosides do not enter cells readily and are 
largely excluded from the central nervous system and the eye. Excretion of 
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aminoglycosides takes place mainly by glomerular filtration in the kidneys and therefore 
dosage adjustments are required in patients with renal impairment [9]. 
4.2.2.1 Neomycin: Neomycin is an aminoglycoside antibiotic and therefore shares the 
features of the family. 
Chemical Structure 
In the neomycin family, there are three amino sugars attached to the central 2- 
deoxystreptamine [5]. 
Figure 2 Structure of Neomycin 
Pharmacokinetics 
Neomycin shares the properties of its parent chemical family aminoglycosides. 
4.2.3 Polymyxins 
Polymyxins are a group of antibiotic substances produced by Bacillus polymyxa [5]. 
They are active against gram negative bacteria. 
Chemical Structure 
Polymyxins are cationic, basic polypeptides with molecular weights of about 1400. All 
contain the fatty acid D-6-methyloctan-l-oic acid and amino acids L-threonine and L-
diarninobutyric acid (DAB) [5, 9]. 
Figure 3 Structure of Polymyxins 
Polymyxin B1 : R = (+)-6-Methyloctanoyl 
Polymyxin B,: R = 6-Methylheptanoyl 
DAB = a, γ-Diaminobutyric Acid 
Mechanism of Action 
Polymyxins attach to cell membranes of bacteria that are rich in 
phosphatidylethanolamine and disrupt the osmotic properties and transport mechanisms 
of the membrane. Thus, polymyxins act like cationic detergents [5, 9]. 
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Pharmacokinetics 
Polymyxin B is not absorbed from the GIT or mucous membranes. At present, it is 
primarily used for topical application. 
4.2.4 Bacitracin 
Bacitracin is an antibiotic produced by Tracy-I strain of Bacillis subtilis [5] and thus its 
name, Baci-tracin. 
Chemical Structure 
Bacitracin is a cyclic polypeptide [5]. 
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Figure 4 Structure of Bacitracin 
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Mechanism of Action 
Bacitracin interferes with the final dephosphorylation in cycling the isoprenylphosphate 
carrier that transfers mucopeptide to the growing cell wall [9]. 
Pharmacokinetics 
Bacitracin is currently used only for topical application. 
4.3 Summary 
From the above discussion on the drug concepts, the importance of the chemical structure 
of the drugs is apparent. Glucocorticoids have a pregnane ring and completely different 
properties and interactions with human bodies than aminoglycosides that contain amino 
sugar linked by glycoside bonds to hexose nucleus. Thus drugs belonging to the same 
chemical family share actions, side effects and clinical usage. Modifications in the 
chemical structure not only change how the body acts on the drug i.e., its absorption, 
transport and elimination but also its actions on the body or other organisms. Minor 
changes in the chemical structure usually change the pharmacokinetics of the drug like 
duration of action. However, major differences in the chemical structure indicate distinct. 
actions. Therefore common chemical structure among pharmacological preparations will 
be the key consideration in determining context while partitioning these concepts in the 
MED sub-net. 
CHAPTER 5 
ANALYSIS RULES 
5.1 Complexity of Class Hierarchy vs. Semantic Network Hierarchy 
At a schema level, complexity was defined in [11] as the ratio of the number of 
relationships to the number of classes. The higher the complexity of a schema the more 
difficult it is to comprehend. It has also been shown in [11] that in a class specialization 
hierarchy, partitioning the classes into contexts and considering the inter-context 
relationships separately from the intra-context relationships (between classes within a 
context), helps in achieving a better understanding of the schema. 
In semantic networks with a concept specialization hierarchy a similar situation 
exists with the difference that the hierarchy nodes do not represent classes but express 
individual concepts with no instances. At the concept level the same quantification of 
complexity i.e., ratio of the number of relationships to the number of concepts, also holds 
true. In the MED, the concepts or terms are considered to be individual objects. Just as 
in the class hierarchy, partitioning applied to a MED sub-net will help in grouping 
concepts into contexts that are easier to comprehend and create object class hierarchies on 
the basis of the emerging contexts. 
5.2 A Methodology for Classifying Concepts in a Semantic Network 
Semantic network vocabularies are difficult to comprehend because they consider each 
term and its associated terms individually without grouping them into logical units. A 
semantic network with a DAG specialization hierarchy structure and superfluous 
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information associated with the concepts makes it even more difficult to understand. It is 
therefore important to provide a means for reducing the information overload in the 
vocabulary network by partitioning the terms into logical units on the basis of context and 
thereby enabling comprehension. 
The method utilized to simplify a complex semantic network schema involves two 
techniques described in more detail in sections 5.2.1 and 5.2.2 {8, 11]: 
1. Informational thinning which removes the information that is not essential to the 
analysis, and 
2. Partitioning which classifies the SUBCLASS-OF relationship into two types so 
that the semantic network DAG is divided into trees. These trees consist of 
concepts in the same context and therefore are more comprehensible. Thus 
turning the original network into a collection of such trees provides greater 
understanding of the whole network. 
5.2.1 Informational Thinning 
A vocabulary semantic network like MED, that contains a vast number of objects, 
relationships and attributes, is difficult to comprehend. The difficulties in understanding 
a vocabulary system arise mainly from the number of relationships associated with the 
concepts. 
In the MED, at the time of this writing, there are 42,744 concepts, 54,547 IS-A 
relationships that connect the concepts to form a DAG and 199,693 other relationships 
used to capture the semantics of the terms. The complexity of the MED is c = (54547 + 
199693) / 42744 = 5.95. 
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Informational thinning allows us to eliminate non-essential information from the 
network by displaying only the properties essential for the analysis. The analysis of the 
MED sub-net, introduced in section 6.1, is based on the IS-A hierarchy only and therefore 
uses this simplified hierarchy with all other attributes and relationships removed from the 
view. This abstraction helps to provide a model of the network that is easier to 
comprehend and is amenable to the partitioning analysis. The complexity of the IS-A 
hierarchy of the MED is 54547/42744 = 1.28. 
The sub-net with the leaf concept CPMC Drug: Cortisporin Opth Oint 
(=opthalmic ointment, an eye ointment) has the most ancestors, 39 (figure 7), of any 
concept in the MED. In this sub-net there are 821 attributes, 62 IS-A relationships and 
157 other relationships. Thus the complexity c = (62 + 157) / (39 + 1) = 5.5. All the 
relationships and attributes with the exception of the IS-A relationship are not required 
for the analysis. Informational thinning allows us to create a simplified hierarchy that has 
the same size (number of concepts) as the original network but fewer relationships 
because only IS-A relationships are represented for the analysis. The complexity of this 
IS-A sub-net is 62/4©= 1.55. Thus the selected sub-net (with complexity 1.55) is more 
complex than any average IS-A sub-net in the MED (with complexity 1.28) and therefore 
partitioning other sub-nets of the MED will be simpler than the current one. 
5.2.2 Partitioning 
Informational thinning removes all the attributes and relationships except the IS-A 
relationship from the sub-net. But still the network is difficult to comprehend due to 
multiple inheritance. Partitioning is used to obtain a set of simple and disjoint smaller 
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sub-hierarchies consisting of concepts in the same context. Partitioning also helps to 
minimize the number of relationships between different logical units of concepts and thus 
reduce the complexity of the sub-net. 
5.2.2.1 Refinement of the SUBCLASS-OF Relation: In the specialization hierarchy 
obtained after Informational Thinning, all the SUBCLASS-OF (IS-A) relationships are of 
the same type. Partitioning divides the objects into logical groups in the same context 
such that each object has only one path in the specialization hierarchy to the root of its 
context. This requires the division of SUBCLASS-OF relationships into two types [11I]: 
1. Category-Of is a specialization relationship which relates the specialization object 
to the more general object where both are in the same application context. These 
are represented in the figures as regular arrows. 
2. Role-Of is a specialization relationship which relates the specialization object to 
the more general object, where the two objects are in different contexts of the 
application. These are represented in the figures as dashed arrows. 
The decision whether a given sub-object relationship in the hierarchy, shown in 
figure 7, is either Category-Of or Role-Of depends on whether the super-object and sub-
object are in the same context or not. This decision lies with the domain expert who 
defines the partitioning rules for a particular domain based on an intuitive understanding 
of the domain. 
As described in the Introduction to Pharmacology (chapter 4), the chemical 
structure of the pharmacological preparations is a key feature in determining the 
properties of a preparation. Therefore the concepts would be classified according to their 
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chemical families. Besides the chemical family the second priority in determining 
context would be given to the site of action and the third to the actions or site of 
productions. 
lnspite of the understanding of the domain and the above mentioned simple 
priority guidelines some rules to resolve difficult cases and ensure consistency are 
required. Disciplined Modeling provides such a set of guidelines that help in the 
partitioning process [8, 11]. 
5.2.2.2 Disciplined Modeling: The partitioning paradigm is supported by the rules of 
Disciplined Modeling which ensure that a forest sub-hierarchy can be identified. 
Disciplined Modeling allows the refinement of the IS-A hierarchy according to three 
rules. 
Rule 1: The equicontext relationship between objects is an equivalence relationship and 
thus partitions the objects of a hierarchy into disjoint contexts. 
This forces the designer to explicitly specify the contexts in the hierarchy and 
leads him to resolve some ambiguous situations especially in situations where contexts 
overlap because a concept belongs to multiple domains. 
Rule 2: Two objects which are Category-Of specializations of a super-object cannot 
have a common. Category-Of descendant object. 
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This rule guarantees that when we refine a general concept represented by an 
object into several sub-concepts in the same context we achieve a partition into mutually 
exclusive concepts. 
Rule 3: For each context there exists one object which is the major (or defining) object 
for this context such that every object in this context is a descendant of this object. 
This means that each context has only one object which is a root for it i.e., there is 
a directed path of the Category-Of relationships from each object of the context.to this 
root object. 
In addition, it has been proved in [8,1 1] that using Disciplined Modeling, an 
object has at most one Category-Of super-object. This theorem guarantees that the 
Category-Of hierarchy has a forest structure. This forest structure is simpler than the 
original DAG and reduces the effort required to comprehend the network. 
5.2.2.3 Type of Role-Of Relationships: In the original MED sub-net, all the super-
object relationships are of the same type i.e., Category-Of. However, in the analysis 
some of these are changed to Role-Of. For most objects with multiple super-objects the 
determination of the defining super-object in the same context is easy yielding a 
Category-Of relationship directed to it. There are a few cases where the decision about a 
definitional super-object for a given object is difficult. In such cases, at most one of the 
several super-objects should have a Category-Of relationship pointing to it, based on the 
Partial context information that has already been accumulated in a processing at that 
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juncture. Such a selection may occur in 3 situations resulting in three types of Role-Of: 
regular Role-Of , Role-Of /Intersection, and Role-Of/Category-Of [8]. 
Case 1: One of the super-objects is definitional while the others are functional. If the 
context of the sub-object is definitional, the sub-object will have a Category-Of 
relationship to the definitional super-object and if the context is functional, then a 
Category-Of relationship to the functional super-object. If there are several functional 
super-objects, the super-object which fits the function described in the context of the sub-
object is selected. The object is Category-Of this primary super-object and Role-Of the 
other super-objects. This kind of Role-Of relationship is a regular Role-Of since a switch 
of context from a super-object to a sub-object has occurred. An example of this case will 
be discussed in section 6.2.1. 
Case 2: All super-objects are definitional with the same importance because each of 
them contributes to the definition of the sub-object in an equal way. In such a situation, 
the object with multiple super-objects would need to be in the context of all its super-
objects. However, by the rules of Disciplined Modeling it cannot belong to more than 
one context. Since both super-objects are of equal importance it would be incorrect to 
associate the object with only one context. Therefore, such an object starts a new context 
which represents the context obtained as an intersection of the contexts of all its super-
objects. Thus, the object is Role-Of all its super-objects. This type of Role-Of is Role-
Of/Intersection represented as r/i in the figures. This is not an actual case of a switch of 
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context but an artificial case due to the requirements of the theorem to forbid two 
Category-Of super-objects. An example of this case will be discussed in section 6.2.1. 
Case 3: The context of the sub-object is a combination of the contexts of its multiple 
super-objects, but one of them contributes more to the meaning than the others. Then the 
Category-Of relationship should point to the preferred super-object. 
5.2.2.4 Diamond Structure: The Role-Of/Intersection gives rise to another situation that 
needs to be resolved so that partitioning into disjoint context is consistent and complete. 
This is the diamond situation as shown in figure 5 where object d is a Role-
Of/11ntersection of its super-objects b and c. 
Figure 5 The Diamond Structure due to Role-Of/11ntersection Relationships 
Since the object d is the intersection of two super-objects, the two super-objects b 
and c cannot both belong to the same context of their super-object a. Otherwise, because 
the intersection of a context with itself will result in the original context, the intersection 
must belong to this common context. Thus the objects h and c are also defined as 
separate contexts. The Category-Of relationship is changed to Role-Of. This kind of 
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Role-Of is described as Role-Of/Category-Of since originally this link was a Category-Of 
relationship but due to Rule 2 it becomes Role-Of and is represented as r/c in the figures 
[8]. 
5.2.2.5 Analysis Sequence for the Sub-net: In the semantic network sub-net from the 
MED, the leaf concepts represent the concepts corresponding most directly to real-world 
objects. A bottom-up analysis in this situation would be appropriate because the context 
of the objects is best evident with the distinct objects at the bottom of the sub-net. This 
knowledge will help to determine which of the contexts of the super-objects fits best with 
the already identified sub-object context especially as the super-objects become more 
generic higher up in the hierarchy. 
CHAPTER 6 
PARTITIONING ANALYSIS OF A SUB-NETWORK OF THE MED 
11n this chapter, partitioning along with rules of Disciplined Modeling are applied to the 
DAG sub-net of the MED to obtain a forest of trees. Each tree produced by the 
partitioning would consist of concepts in the same context. 
6.1 Introduction to the MEI) Sub-net 
The objective of this thesis is to analyze and partition the most complex hierarchical sub-
net in the MED. This sub-net is the one with the leaf that has the maximum number of 
ancestors. This sub-net is in the pharmacy domain and consists of ancestors of the leaf 
concept CPMC Drug: Cortisporin Opth Oint (MED-CODE 28602). In order to enable 
understanding of the sub-net, figure 7 shows the sub-net after Informational Thinning has 
been applied leaving only the IS-A relationships in the sub-net. In the following 
discussion the attribute names of the objects (or concepts) are followed by their slot ID 
numbers in parenthesis. 
The root of this sub-net is the concept Medical Entity. As we move down the 
hierarchy the concepts become more specific. The concept Medical Entity provides 10 
basic properties that constitute the minimal set of properties describing each concept in 
the vocabulary. This basic set consists of the attributes MED-CODE (0), UMLS-CODE 
(1), NAME (2), SUBCLASS-OF (4), SYNONYM (5), PRINT-NAME (6), HAS-PART 
(7), PART-OF (8), MAIN-MESH (50) and SUPPLEMENTARY-MESH (51) that are 
common to all the MED entities. 
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The concepts in the pharmacy domain can be viewed from various perspectives. 
Each of these perspectives describes one or more specific properties of that concept and 
classifies them according to this property. The top level ancestors of the pharmacy 
concepts correspond to the various classifications of drugs. 
Two major classifications in the sub-net are the concepts CPMC Formulary Drug 
Item and American Hospital Formulary Service (AHFS) Class. The concept AHFS Class 
introduces the attribute AHFS-CLASS-CODE (55) that is used to map each descendant 
of the concepts CPMC Formulary Drug Item to Al-IFS Class code. Both these 
formularies group drugs according to their action (like the concepts Anti-Infective Agents 
and Anti-11nflammatory Agents), site of action (like the concepts Eye, Ear, Nose & Throat 
(EENT) Preparations, Skin and Mucous Membrane Agents) or biological existence in the 
human body (like the concept Hormones and Synthetic Substitutes). The concept 
Hormones and Synthetic Substitutes further classify concepts according to their 
physiological source like the concept Adrenal Agents that refers to substances produced 
by adrenal glands. 
Drugs having similar actions are further classified according to their chemical 
families. 11n the sub-net, the concept Antibiotic Preparations is sub-classified into 
concepts Aminoglycoside Preparations and Miscellaneous Antibiotics groups and 
similarly the concept Anti-Inflammatory Agents into concepts Glucocorticoids Agents 
and non-steroidal families (not shown in the sub-net). 
Other classifications group drugs on the basis of other properties. The Drug 
Enforcement Agency (DEA) Controlled Substance Category concept classifies drugs 
according to its abuse potential and introduces attribute DEA-CODE (73). The attribute 
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ALLERGY-CLASS-CODE (70) is introduced by the concept Drug Allergy Class. The 
allergic effects are characteristics of the chemical ingredients of the preparations and 
therefore are classified according to the chemical families like the concepts Drug Allergy 
Class: Glucocorticoid and Drug Allergy Class: Aminoglycoside. 
The attribute DRUG-DESCRIPTION (71) is introduced by the concept CPMC 
Formulary Drug Forms that specifies its form of dispensation. The actual prescribed 
preparations, which are the leaves in the sub-net, can be dispensed in various forms like 
tablets, by milligram or grams. Only the leaf nodes which are the actual real world 
objects or dispensed drugs can be descendants of this concept. 
The concept Pharmacy Items (Drug and Nondrugs) introduces a host of properties 
for its descendants that define pharmaceutical preparation concepts. 
The Orderable Entity concept is the ancestor of any concept that represents 
something that can be ordered like a drug as a descendant of the concept Pharmacy Item 
(Drugs or Nondrugs) or a special diet as a descendant of the concept Prescribed Diet (not 
shown in the sub-net). 
The concepts in the middle of the sub-net describe various individual preparations 
that are dispensed as single component drugs like Neosporin Preparations, Bacitracin 
Preparations, Polymyxin B Preparations and Hydrocortisone Preparations (figure 7). 
These individual single drug preparations form the ancestors of drug combinations like a 
combination of two different antibiotics may be used to enhance the spectrum against the 
organism while reducing the dosage of each agent to reduce the side effects (Bacitracin/ 
Polymyxin B Combination Preparations). Drugs may also be combined with other drugs 
with different actions. An antibiotic preparation may be combined with an anti- 
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inflammatory one like the concept Hydrocortisone/Neomycin /Polymyxin B Combination 
Preparations. This combination would act against the infecting bacteria and also provides 
relief from inflammation induced by the infection. 
Finally we reach the leaves that are the actual preparations provided to the 
patients. These may be a single drug represented by the concept CPMC Drug: Bacitracin 
Oint 30 Gm or a combination like CPMC Drug: Cortisporin Opth Oint that is the focus of 
our analysis in this thesis. 
Some of the concepts that are not ancestors of the concept CPMC Drug: 
Cortisporin Opth Oint like CPMC Drug: Cortisporin Otic Soln 10 ml (ear drops), CPMC 
Drug: Neosporin GU Irrigent 1 ml amp, CPMC Drug: Bacitracin Oint 30 Gm, CPMC 
Drug: Neosporin Topical Oint 30 Gm and CPMC Drug: Polymyxin B Sulf 500,000u pwd 
are also included in the sub-net. These concepts help in resolving the context issues in 
difficult cases during the analysis. 
The Leaf Concept CPMC Drug: Cortisporin Opth Oint 
All the features of the concept CPMC Drug: Cortisporin Opth Oint are captured in these 
tuples for the concept in the MED flat file as shown in figure 6. 
The NAME (2) of the preparation is CPMC DRUG: CORTISPORIN OPTH 
OINT and its PRINT-NAME (6) is CPMC Drug: Cortisporin Opth Oint. It is 
SUBCLASS-OF (4) concepts Eye, Ear, Nose and Throat Antibiotic (MED-CODE 24077) 
indicating its site and effect, Drugs Dispensed by the Gram (MED-CODE 28308) that 
indicates its form of dispensation and Bacitracin/Hydrocortisone/Neomycin/Polymyxin B 
Combination Preparations (MED-CODE 32818) that supplies its chemical constituents. 
28602,1," 
28602,2,''CPMC DRUG: CORTISPORIN OPTH OINT" 
28602,4,24077 
28602,4,28308 
28602,4,32818 
28602,5," 
28602,6,"CPMC Drug: Cortisporin Opth Oint" 
28602,7, 
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28602,59,"COROO" 
28602,60:00081019786" 
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28602,62,"NEOMYCIN/BACITRACIN/POLY/HC" 
28602,63,"BURROUGHS" 
28602,64,"F" 
28602,65,"3" 
28602,66,"N" 
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28602,69,"0" 
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28602,70,"10" 
28602,71,"GM" 
28602,72,"0" 
28602,73:0" 
28602,74,"Q6W" 
28602,75,"87269" 
28602,76:819" 
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28602,112,30379 
28602,113,30430 
28602,113,30632 
28602,113,30730 
28602,113,30776 
28602,123:00000447" 
28602,132," 
Figure 6 Flat File Abstract for the Concept CPMC Drug: Cortisporin Opth Oint 
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It has no synonyms and therefore SYNONYMS (5) is a null string. Its AHFS-CLASS-
CODE (55) is 520404. Since it is an ointment it is not measured in dose and therefore its 
DOSE-STRENGTH-UNITS (56) is not applicable, its DOSE-STRENGTH-NUMBER 
(57) is 0.0 and DRUG-VOLUME (69) is 0. Its FORMULARY-NAME (58) is 
CORT11SPORIN OPTH OINT and SHORT-FORMULARY-NAME (59) is COROO 
which is a concatenation of the CORtisporin Ophthalmic Ointment. It FORMULARY-
CODE (60) is 00081019786 and its DRUG-TRADE-NAME (61) is CORTISPORIN. Its 
DRUG-GENERIC-NAME (62) is its components chemicals, NEOMYCIN / 
BACITRACIN / POLY / HC and DRUG-MANUFACTURER (63) is BURROUGHS. 
Its DRUG-ROUTE (67) i.e., route of administration, is OPTHalmic i.e., to be applied to 
the eye. Its DRUG-DESCRIPTION (71) indicates its is dispensed by grams and its DEA-
CODE (73) indicates it belongs to DEA category 0 i.e., those drugs that have no abuse 
potential. 11ts two instances of ALLERGY-CLASS-CODE (70) indicates it can have two 
types of allergic reactions, one due to Aminoglycoside components and one due to 
Hydrocortisone. Its PHARMACEUTIC-COMPONENTs (113) are Bacitracin (MED-
CODE 30430), Hydrocortisone (MED-CODE 30632), Polymyxin B (MED-CODE 
30776) and Neomycin (MED-CODE 30730). The other properties are for internal use of 
CPMC. 
Thus, the attributes and relationships for the concept CPMC Drug: Cortisporin 
Opth Oint capture all the essential features that might be queried by the physician, 
pharmacist, the DEA or any other user of medical information. 
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6.2 Applying Partitioning. Methodology to the Complex Sub-net 
In this section, partitioning along with the rules of Disciplined Modeling are applied to 
the DAG sub-net of the MED to obtain a forest of trees. Each tree produced by the 
partitioning would consist of concepts (or objects) that are in the same context. One of 
the concept (or object) in each tree, usually the root of that tree, defines the unifying 
context for all the concepts in that tree. 
The partitioning will be carried out in a bottom-up manner and involves two 
passes: 
I. 	 Classification of the IS-A relationships, and 
2. 	 Resolution of any diamond structures that would be a contradiction for 
Disciplined Modeling. 
6.2.1 Classification of the IS-A Relationships 
The hierarchical sub-net shown in figure 7 includes all the ancestors of the object CPMC 
Drug: Cortisporin Opth Oint (MED-CODE 28602) in which all the super-object 
relationships are of the same type. In the following description the objects are followed 
by numbers in parentheses that identify them in the accompanying figures. 
The object at the bottom of the hierarchy, CPMC Drug: Cortisporin Opth Oint (2), 
has three super-objects, Bacitracin / Hydrocortisone / Neomycin / Polymyxin B 
Combination Preparations (3), Drugs Dispensed by the Gram (23) and Eye, Ear, Nose and 
Throat Antibiotics (28). The super-object 3 defines the chemicals constituents of the 
object 2. The super-object 23 specifies the dispensation form of the drug. Other siblings 
of 23 are Tablets, Drugs Dispensed by the Milliliter and Drugs Dispensed by the 
47 
Figure 7 Most Complex Sub-net in the MED after Informational Thinning 
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Milliequivalents (not shown in the figures), that specify some other forms of drug 
dispensation. The super-object 28 specifies the site (eye, ear, nose and throat) and action 
(antibiotic) of the object 2. The ingredients of the ointment uniquely define the properties 
of the object 2. Neither super-objects, 23 or 28, define the context of object 2. Therefore 
by Case 1 of Disciplined Modeling, the object 3 is the primary super-object and the 
object 2 is Category-Of 3, Role-Of 23 and Role-Of 28. 
The object Bacitracin / Hydrocortisone / Neomycin / Polymyxin B Combination 
Preparations (3), has two super-objects, Bacitracin / Neomycin / Polymyxin B 
Combination Preparations (5) and Hydrocortisone / Neomycin / Polymyxin B 
Combination Preparations (7). Both these super-objects contribute the properties of 
Neomycin Preparations and Polymyxin B Preparations to the object 3. In addition, 5 
adds properties of Bacitracin Preparations and 7 adds features of Hydrocortisone 
Preparations. The four chemical constituents together define the object 3. Therefore by 
Case 2 it is not possible to associate 3 with one of the super-objects and it is a Role-Of 
both objects 5 and 7. This Role-Of is a result of intersection of the properties of the 
super-objects and is of type Role-Of/Intersection. 
A similar analysis can be applied to all objects that are roots of drug combinations 
like Bacitracin / Neomycin / Polymyxin B Combination Preparations (5) that is Role-Of 
both Bacitracin / Polymyxin B Combination Preparations (13) and Neomycin / 
Polymyxin B Combination Preparations (8). Similarly, Hydrocortisone / Neomycin / 
Polymyxin B Combination Preparations (7) becomes Role-Of its super-objects Neomycin 
/ Polyrnyxin B Combination Preparations (8) and Topical Hydrocortisone Preparations 
(15), while Bacitracin / Polymyxin B Combination Preparations (13) is Role-Of both 
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Bacitracin Preparations (14) and Polymyxin B Preparations (26). Finally, the object 
Neomycin / Polymyxin B Combination Preparations (8) becomes Role-Of both its super-
objects Neomycin Preparations (10) and Polymyxin B Preparations (26). 
The object Topical Hydrocortisone Preparations (15) has two super-objects, 
Hydrocortisone Preparations (16) and Skin and Mucous Membrane Anti-inflammatory 
Agents (36). The super-object 16, an adrenal steroid having a 
cyclopentenoperhydrophenanthrane ring structure, defines the chemical structure for 15 
while super-object 36 defines the action (anti-inflammatory) and the site of the action 
(skin and mucous membrane or topical). Thus the structural definition for 15 is provided 
by the super-object 16 and the object 15 is Category-Of 16 and Role-Of 36. 
The object Neomycin Preparations (10) also has two super-objects, 
Aminoglycoside Preparations (20) and Drug Enforcement Agency (DEA) Class 0-Drug 
without Abuse Potential (17). The object 10 is one of the arninoglycoside antibiotics that 
are characterized chemically by amino sugars linked by a glycoside bond to an 
aminocyclitol ring [5,12]. The super-object 17 indicates a grouping used by the DEA to 
identify preparations like 10 that do not have abuse potential but this does not add to the 
properties of 10. Therefore 10 is Category-Of 20 and Role-Of 17. 
The object Bacitracin Preparations (14) has two super-objects, Miscellaneous 
Antibiotics (27) and Drug Enforcement Agency (DEA) Class 0-Drug without Abuse 
Potential (17). The 27 group is a heterogeneous group of antibiotics that have chemical 
structures that do not fall into the major antibiotic families represented by objects like 
Penicillin Preparations or Aminoglycoside Preparations. Some of the sub-objects of 
Miscellaneous Antibiotics are Vancomycin Preparations (a glycopeptide), Polymyxin B 
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Preparations (26) (a basic polypeptide) and Clindamycin Preparations (a lincosamide) and 
Bacitracin Preparations (a cyclic polypeptide) (14) [5, 9, 12]. The super-object 17, like in 
the case of object 10, does not provide any definitional property to object 14. Therefore 
14 is Category-Of 27 and Role-Of 17. On a similar note Polymyxin B Preparations (26) 
(another sibling of Bacitracin Preparation) is also Category-Of 27. 
The object Hydrocortisone Preparations (16) has three super-objects, 
Glucocorticoid Agents (33), Drug Enforcement Agency (DEA) Class 0-Drug without 
Abuse Potential (17) and Drug Allergy Class: Glucocorticoids (19). All glucocorticoids 
have a cyclopentenoperhydrophenanthrane ring structure that is responsible for their 
common family properties. The super-object 33 defines the chemical structure for 16. 
Some other glucocorticoid agents in the MED that share the structure and properties of 16 
are objects like Prednisolone Preparations, Methyl-prednisolone Preparations, 
Triamicinolone Preparations, Betamethasone Preparations and Dexamethasone 
Preparations (not shown in the figures). The super-objects 17 (that groups drugs 
according to abuse potential) and 19 (that groups the drugs according to its allergic 
potential) do not define any structural feature of 16. Hence, 16 is Category-Of 33, Role-
Of 17 and Role-Of 19. 
The object Aminoglycoside Preparations (20), has super-objects Antibiotic 
Preparations (29) and Drug Allergy Class: Aminoglycosides (21). The object 29 is a 
heterogeneous concept that defines the action (antibiotic) of object 20 rather than its 
chemical structure. The object 20 is a major antibiotic chemical family among others like 
Penicillin Preparations and Cephalosporin Preparations (not shown in the figures). The 
object 21 indicates the allergic effects of preparations belonging to domain of object 20. 
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Hence 20 is not in the same context with either of the super-objects 21 or 29. It defines a 
new context for its descendants and is therefore Role-Of both 21 and 29. 
The object Miscellaneous Antibiotics (27) has one super-object, Antibiotic 
Preparations (29). The super-object 29 defines the group of drugs that have antibiotic 
effects and does not define any chemical structure for 27. Other siblings of 27 in the 
MED include the major antibiotic families like the objects Penicillin Preparations, 
Arninoglycoside Preparations and Tetracycline Preparations each defining the basic 
chemical structure for their descendant objects. Similarly, the object 27 also defines a 
group of antibiotics without any specifying their chemical structure. Therefore the object 
27 is Category-Of 29. 
The object Eye, Ear, Nose and Throat Antibiotics (28) has super-objects 
Antibiotic Preparations (29) and Eye, Ear, Nose and Throat Anti-Infectives (30). The 
object 28 defines the site (eye, ear, nose and throat) and the type of action (antibiotic) for 
its descendants. The super-object 29 indicates only the type of action (antibiotic) where 
the super-object 30 indicates both the site and action. Therefore 28 is Role-Of 29 and 
Category-Of 30. 
The object Eye, Ear, Nose and Throat Anti-Infectives (30) has two super-objects, 
Anti-Infective Agents (31) and Eye, Ear, Nose and Throat Preparations (32). The super-
object 31 defines the actions of 30 and super-object 32 identifies its site. As discussed 
previously, site of action is given a higher preference in deciding the context of an object 
and therefore 30 is Category-Of 32 and Role-Of 31. 
The object Glucocorticoid Agents (33) has two super-objects, Adrenal Agents 
(34) and Anti-Inflammatory Agents (37). Glucocorticoids are chemicals that are secreted 
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by adrenal glands and super-object 34 indicates the physiological source for 33. Another 
type of adrenal agents are mineralocorticoids which are functionally distinct from 
glucocorticoids. The super-object 37 is a heterogeneous set of concepts that includes 
steroidal anti-inflammatory drugs like Glucocorticoid Agents and non-steroidal anti-
inflammatory agents like the objects Aspirin Preparations, Ibuprofen Preparations or 
Phenylbutazone Preparations (not shown in the figures). Therefore neither of the super-
objects define the properties for object 33 and so it is a Role-Of both 34 and 37. The 
object 33 defines a new context consisting of objects Hydrocortisone Preparations, 
Betamethasone Preparations and Dexamethasone Preparations (not shown in the figures) 
that belong to the same chemical family. 
The object Adrenal Agents (34) had one super-object Hormones and Synthetic 
Substitutes (35). Adrenal Agents are hormones that are produced by adrenal glands and 
therefore the object 34 is Category-Of 35. 
The object Skin and Mucous Membrane Anti-Inflammatory Agents (36) has two 
super-objects, Skin and Mucous Membrane Agents (38) and Anti-Inflammatory Agents 
(37). The object 36 indicates a site (skin and mucous membrane) and an action (anti-
inflammatory). The super-object 38 defines the site while 37 defines the action. The 
super-object 37 has children which define different types of chemicals having anti-
inflammatory properties or different sites where anti-inflammatory agents can be applied. 
Here, once again, the site is considered more important in determining the context of the 
object. Therefore 36 is Category-Of 38 and Role-Of 37. 
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The object Antibiotic Preparations (29) has one super-object, Anti-Infective 
Agents (31). Since antibiotic substances are a type of anti-infective agents that are 
produced by living organisms, 29 is a Category-Of 31. 
The object Anti-Infective Agents (31) has two super-objects, CPMC Formulary 
Drug Item (39) and American Hospital Formulary Service Class (42). Both 42 and 39 
define formulations of various pharmacological preparations according to the action or 
site of application or physiological existence in the body. Therefore 31, which specifies a 
particular action of its domain objects, is not in the same context with any of the 
formularies. Hence 31 is Role-Of both 39 and 42. The objects Eye, Ear, Nose and 
Throat Preparations (32), Hormones and. Synthetic Substitutes (35), Anti-Inflammatory 
Agents (37) and Skin and Mucous Membrane Agents (38) all have the two super-objects 
39 and 42. All of these, like 31, are Role-Of their super-objects. 
The object Drug Enforcement Agency (DEA) Class 0-Drugs without Abuse 
Potential (17) has one super-object, Drug Enforcement Agency Controlled Substance 
Category (18). The super-object 18 is in the same context as the object 17 i.e., a 
classification of the drugs according to DEA. Therefore 17 is a Category-Of 18. On a 
parallel analysis object Drug Allergy Class: Glucocorticoid (19) is a Category-Of Drug 
Allergy Class (22) and so is object Drug Allergy Class: Aminoglycoside (21). 
The object Drugs Dispensed by the Gram (23) has one super-object, CPMC 
Formulary Drug Form (24). The object 24 defines all the forms in which a drug may be 
dispensed. The object 23 is one of the forms of drug dispensation along with other forms 
like the concept Dispensed by the Milligrams etc. Therefore the object 23 is Category-Of 
24. 
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Figure 8 Sub-net after Classifying IS-A Relationships 
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The object CPMC Formulary Drug Item (39) has one super-object, Pharmacy 
Items (Drugs and Nondrugs) (40). The objects 39 and 40 are in the same context because 
CPMC Formulary Drug Item is one of the Pharmacy Items. 
The object Drug Enforcement Agency (DEA) Controlled Substance Category (18) 
has one super-object, Pharmacy Concepts (41). The super-object 41 is a generic term that 
has sub-objects referring to different contexts. One of the sub-objects of 41 is Drug 
Enforcement Agency (DEA) Controlled Substance Category (18) that defines drug 
concepts that are controlled by DEA. Another sub-object of 41 is Drug Allergy Class 
(22) that groups concepts according to its allergic properties. Still another is CPMC 
Formulary Drug Forms (24) that refers to the dispensation form (tablet, injectable etc). 
Therefore each of the sub-objects of 41 is a specialization in a different context making 
all its sub-objects (18, 22, 24) Role-Of 41. 
The object Pharmacy Items (Drugs and Nondrugs) (40) has super-objects 
Pharmacy Concepts (41) and Orderable Entity (45). Based on the analysis of objects 18, 
22 and 24, the object 40 is Role-Of 41. Also 45 is a heterogeneous group of objects that 
can be ordered that may be pharmacy or non-pharmacy concepts like Prescribed. Diet (not 
shown in the figures). Therefore 40 is not in the same context as 45 and is a Role-Of 45. 
The object American Hospital Formulary Service Class (42) has one super-object, 
Classification (43). AHFS Class is a type of classification and therefore Category-Of 43. 
Similarly, the object Pharmacy Concepts (41) has one super-object Classification (43) 
and is a Category-Of 43. 
The objects at the top level including Classification (43), Intellectual Product (44), 
Conceptual Entity (46) and Orderable Entity (45) have only one super-object (44, 46, 47 
Figure 9 Sub-net after Resolving Diamond Structure 56 
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and 46 respectively). All of them are generic concepts like Medical Entity (47) and 
therefore are Category-Of their super-objects. 
The results of the classification of IS-A relationships is shown in figure 8 with all 
Category-Of as solid lines and all Role-Of as dashed lines. 
6.2.2 Resolving the Diamond Structure 
After the first pass, the resulting partitioned contexts must be examined to determine if 
there are any contradictions to the rules of Disciplined Modeling produced by a diamond 
structure for the Role-Of/Intersection type of IS-A relationships. A diamond structure 
can be identified by an ordered pair <a, b> where a represents the upper vertex and b the 
lower vertex. In the figure 8 the diamond structures present are <3,8>, <7,17>, <7,39>, 
<7,42>, <5,26>, <8,29> and <13,27>. All of these except <13, 27> satisfy the rules of 
Disciplined Modeling. In the case of <13, 27> diamond, the sub-object 13 is the 
intersection of 14 and 26 with both contributing defining components to 13. Thus 13 is a 
Role-Of/Intersection of both 14 and 26. However, in the first pass of the analysis both 14 
and 26 were considered to be Category-Of 27 and this contradicts the Disciplined 
Modeling Rule 2 and therefore both relationships are changed to Role-Of/Category-Of 27 
(shown as r/c in the figure). 
Figure 9 shows the sub-net after resolution of the diamond structure. 
6.2.3 Results 
Figure 9 presents the result of the analysis after the partitioning is complete. As can be 
seen in figure 10, with the removal of the Role-Of relationships, the objects are now 
Figure 10 Partitioned Sub-net with only Category-Of Relationships 
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grouped into units that are in the same context. The Role-Of relationships can be utilized 
for inheritance of properties but for simplifying the sub-net and to enable comprehension 
they are removed to produce the following logical groups : 
1. Bacitracin/Hydrocortisone/Neomycin/Polyrnyxin B Combination Preparations 
group that consists of 3 and 2. 
2. Hydrocortisone/Neomycin/Polymyxin B Combination Preparations group consists 
of objects 7 and 6 (not an ancestor of 2). 
3. Bacitracin/Neomycin/Polymyxin B Combination Preparations group consisting of 
5 and 4 (not ancestor of 2). 
4. Bacitracin/Polymyxin B Combination Preparations group consisting of 13 and 12 
(not ancestor of 2) 
5. Neomycin/Polymyxin B Combination Preparations group consisting of 8 and 1 
(not ancestor of 2) 
6. Polymyxin B Preparations group consisting of 26 and 25 (not ancestor of 2) 
7. Bacitracin Preparations group consisting of 14 and 11 (not ancestor of 2) 
8. Glucocorticoid Agents group consisting of 33, 16 and 15 
9. Aminoglycoside Preparations group consisting of 20, 10 and 9 (not ancestor of 2) 
10. Anti-Infective Agents group consisting of 31, 29 and 27 
11. EENT Preparations group consisting of 32, 30 and 28 
12. Hormones and Synthetic Substitutes group consisting of 35 and 34 
13. Anti-Inflammatory Agents group consisting of 37 
14. Skin and Mucous Membrane Agents group consisting of 38 and 36 
60 
15. DEA Controlled Substance Category group consisting of 18 and 17 
16. Drug Allergy Class group consisting of 22, 19 and 21 
17. CPMC Formulary Drug Forms group consisting of 24 and 23 
18. Pharmacy Items group consisting of 40 and 39 
19. Medical Entity group consisting of 47, 46, 45, 44, 43, 42 and 41 
The size of the sub-net remains 40 while the number of relationships (Category-
Of) is now 21 (not including the objects that are not ancestors of the leaf CPMC Drug: 
Cortisporin Opth Oint). Therefore the complexity is reduced from 1.55 to 0.525 i.e., a 
much simpler hierarchy. In fact with the emergence of the forest structure, the maximum 
complexity would be 39/40 if it were a spanning tree. 
Also the number of contexts will not increase dramatically if more objects are 
added to the sub-net but remains quite stable. The concept Aminoglycoside Preparations 
generically represents objects like Streptomycin Preparations, Kanamycin Preparations 
and Amikacin Preparations (which are not shown in the sub-net) and even when these 
objects are added as children of the object Aminoglycoside Preparations the number of 
contexts remains unchanged. Similarly, adding siblings to the object Hydrocortisone 
Preparations like the objects Prednisolone Preparations and Triamcinolone Preparations, 
they will once again be absorbed in the group Glucocorticoid Agents with no additional 
comprehension effort required. 
Hence, partitioning is a powerful tool that reduces the DAG specialization 
hierarchy to a more comprehensible forest of trees. 
CHAPTER 7 
CONCLUSIONS 
From the experience gained in the partitioning of the most complex sub-net of the MED, 
it is apparent that context partitioning of the DAG sub-net into tree sub-hierarchies 
reduces the complexity of the sub-net and aids comprehension. In the pharmacy domain 
the chemical structure was deemed to be the most important feature for identifying 
objects in the same context. This methodology can be extended to other domains of 
medicine by identifying the respective context defining features. In the disease domain 
the etiology and site of disease can uniquely identify the disease and in the lab domain 
the substance being detected and the test specimen can identify the tests that are in the 
same context. In this way partitioning can be applied to the complete the MED network 
resulting in class hierarchies that simplify the network and help in comprehension and 
management of information. 
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APPENDIX A 
MED SLOT FILE 
0,"MED-CODE",1,-1,0„"IDENTIFIER" 
1,"UMLS-CODE",1,-1,0„"IDENTIFIER" 
2,"NAME",1,-1,0„" SYNONYM" 
3,"DESCENDANT-OF",1,0,1,-2, 
4,"SUBCLASS-OF",1,0,0,-1, 
5," S YNONYMS",1,-1,0„" SYNONYM" 
6,"PRINT-NAME",1,-1,0„"SYNONYM" 
7,"HAS-PARTS",1,1,1,8, 
8,"PART-OF",1,0,1,7, 
9," CPMC-LAB-PROC-CODE",144,-1,0„"IDENTIFIER" 
10," SERVICE-CODE",144,-1,0„"IDENTIFIER" 
11,"CPMC-UNIT-NAMES",144,-1,0„"NAME" 
12," CPMC-LAB-TEST-NAMES",2248,-1,0„"NAME" 
13 ,"SPECIMEN-OF",49,0,1,14, 
14,"SPECIMEN",93,1,1,13, 
15,"MEASURED-BY",50,0,1,16, 
16,"SUBSTANCE-MEASURED",93,1,1,15, 
17,"UNITS",94,-1,0„"SHORT_STRING" 
18,"RESULT-OF-TESTS",83,0,1,23, 
19," CPMC-LAB-PROC-NAME",144,-1,0„"NAME" 
20,"CPMC-LAB-TEST-CODE",2248,-1,0„"IDENTIFIER" 
21,"CPMC-LAB-SPEC-CODE",49,-1,0„"IDENTIFIER" 
22,"CPMC-LAB-SPEC-NAME",49,-1,0„"NAME" 
23,"RESULT-TYPE",94,1,1,18, 
24,"CPMC-SMEAR-CODE",1067,-1,0„"IDENTIFIER" 
25 ,"CPMC-SMEAR-NAME",1067,-1,0„"NAME" 
26,"CPMC-PANEL-CODE",1286,-1,0„"IDENTIFIER" 
27,"CPMC-PANEL-NAME",1286,-1,0„"NAME" 
28,"CPMC-PREFIX-CODE",1035,-1,0„"IDENTIFIER" 
29,"CPMC-PREFIX-NAME",1035,-1,0„"NAME" 
30," CPMC-RESULT-CODE",315,-1,0„"IDENTIFIER" 
31," CPMC-RESULT-NAME",315,-1,0„"NAME" 
32,"CPMC-SENSITIVITY-NAME",1181,-1,0„"NAME" 
33 ,"CPMC-SENSITIVITY-RESULT-NAME",1066,-1,0„"NAME" 
34,"ETIOLOGY",76,0,1,35, 
35,"CAUSES-DISEASES",135,1,1,34, 
36,"SITE",76, 11 ,1,37, 
37,"SITE-OF-DISEASES",14,0,1,36, 
38,"NORMAL-VALUE",2248,-1,0„"SHORT_STRING" 
39,"LOW-NORMAL-VALUE",2248,-1,0„"SHORTS_TRING" 
40,"HIGH-NORMAL-VALUE",2248,-1,0„"SHORT_STRING" 
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41,"MALE-LOW-NORMAL-VALUE",2248,-1,0„"SHORT_STRING" 
42,"MALE-HIGH-NORMAL-VALUE",2248,- 1 ,O„" SHORT STRING" 
43,"FEMALE-LOW-NORMAL-VALUE",2248,-1,0„"SHORT STRING" 
44,"FEMALE-HIGH-NORMAL-VALUE",2248,-1,0„"SHORTISTRING" 
45,"NORMAL-RANGES-TEXT",144,-1,0„"LONGSTRING" 
46," CPMC-ECG-NAME",2314,-1,0„"NAME" 
47," SUB STANCE-SAMPLED",49,1,1,115, 
48,"ICD9-CODE",21762,-1,0„"IDENTIFIER" 
49,"ICD9-ENTRY-CODE",21762,-1,0„"IDENTIFIER" 
50,"MAIN-MESH",1,-1,0„"LONG STRING" 
51," SUPPLEMENTARY-MESH",1,-1,0„"LONG STRING" 
52,"QUESTION-TYPE",14870,-I,0„"IDENTIFIER" 
53,"ENGLISH-QUESTION",14870,-1,0„"LONG STRING" 
54,"BRS-QUESTION",14870,-1,0„"LONG STRING" 
55,"AHFS-CLASS-CODE",23147,-1,0„"IDENTIFIER" 
56,"DOSE-STRENGTH-UNITS",28103,-1,0„" SHORT STRING" 
57,"DOSE-STRENGTH-NUMBER",28103,-1,0„"SHORT_STRING" 
58,"FORMULARY-NAME",28103,-1,0„"NAME" 
59,"SHORT-FORMULARY-NAME",28103,-1,0„"NAME" 
60,"FORMULARY-CODE",28103,-1,0„"IDENTIFIER" 
61,"DRUG-TRADE-NAME",28103,-1,0„"NAME" 
62,"DRUG-GENERIC-NAME",28103,-1,0„"NAME" 
63,"DRUG-MANUFACTURER",28103,-1,0„"NAME" 
64,"DRUG-RX-VS-OTC",28103,-1,0„" SHORT STRING" 
65," DRUG-FORM-CODE",28103,-1,0„"IDENTIFIER" 
66,"DRUG-FLOOR-STOCK",28103,-I,0„" SHORT STRING" 
67,"DRUG-ROUTE",28103,-I,0„"SHORT STRING" 
68,"DRUG-IN-FORMULARY",28103,-1,0„"SHORT STRING" 
69,"DRUG-VOLUME",28103,-1,0„"SHORT STRING" 
70,"ALLERGY-CLASS-CODE",28109,-1,0„"IDENTIFIER" 
71,"DRUG-DESCRIPTION",28202,-1,0„"SHORT STRING" 
72,"DRUG-CATEGORY",28103,-1,0„"SHORT_STRING" 
73,"DEA-CODE",28104,-1,0„"I DENTIFIER" 
74," DRUG-SPECIFIER",28103,-1,0„" SHORT STRING" 
75,"DRUG-GENERIC-CODE",28103,-1,0„" SHORT STRING" 
76,"DRUG-INTERACTION-CODES",28103,-1,0„"SHORT_STRING" 
77,"EVENT-ID",9876,1,1,78, 
78,"EVENT-ID-OF",1178,0,1,77, 
79,"EVENT-DATE",9876,1,1,80, 
80,"EVENT-DATE-OF",30349,0,1,79, 
81,"EVENT-PATIENT-ID",9876,1,1,82, 
82,"EVENT-PATIENT-ID-OF",1178,0,1,81, 
83,"EVENT-PARTICIPANT'',9876,1,1,84, 
84,"PARTICIPANT-OF",30352,0,1,83, 
85,"EVENT-ORGANIZATION",9876,1,1,86, 
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86,"EVENT-ORGANIZATION-OF",1178,0,1,85, 
87,"EVENT-LOCATION",9876,1,1,88, 
88,"EVENT-LOCATION-OF",1178,0,1,87, 
89,"EVENT-STATUS",9876,1,1,90, 
90,"STATUS-OF",30355,0,1,89, 
91,"ORDER-QUANTITY",30344,1,1,92, 
92," ORDER-QUANTITY-OF",30350,0,1,91, 
93," ORDER-FREQUENCY",30344,1,1,94, 
94," ORDER-FREQUENCY-OF",32504,0,1,93, 
95,"PROTOCOL-NAME",32979,-1,0„"NAME" 
96,"PROTOCOL-SHORT-NAME",32979,-1,0„"NAME" 
97," ORDER-START-DATE",30344,1,1,98, 
98,"ORDER-START-DATE-OF",30349,0,1,97, 
99," ORDER-STOP-DATE" ,30344,1,1,100, 
100,"ORDER-STOP-DATE-OF",30349,0,1,99, 
101,"PHARMACY-ORDER-CODE",30343,-1,0„"IDENTIFIER" 
102,"STATUS-CODE",30355,-1,0„"IDENTIFIER" 
103,"PARTICIPANT-ID",30352,1,1,104, 
104,"PARTICIPANT-ID-OF",1178,0,1,103, 
105,"ORDER-VALUE",30363,1,1,106, 
106,"ORDER-VALUE-OF",1178,0,1,105, 
107,"ORDERED-DRUG",30365,1,1,108, 
108,"ORDERED-IN",28103,0,1,107, 
109,"DRUG-ROLE-CODE",30365,-1,0„"IDENTIFIER" 
11 1 0,"PHARMACY-OBSERVATION-CODE",30374,-1,0„"IDENTIFIER" 
1 111,"OBSERVED-ALLERGY",30379,1,1,112, 
112,"ALLERGY-OBSERVED-IN",28109,0,1,111, 
113 ,"PHARMACEUTIC-COMPONENT" ,28103,1,1,114, 
114,"PHARMACEUTIC-COMPONENT-OF",43,0,1,113, 
I 15,"SAMPLED-BY",32291,0,1,47, 
116,"ADMIN-FREQUENCY-ABBREV",32431,-1,0„"NAME" 
117,HL7-EVENT-CODE",32466,-1,0„"IDENTIFIER" 
118,"EVENT-OBJECT",30344,1,1,119, 
119,"OBJECT-OF-EVENT",32505,0,1,118, 
120,"OLD-ICD9-CODE",21762,-1,0„"IDENTIFIER" 
121,"PARTICIPANT-NAME",30352,1,1,122, 
122,"PARTICIPANT-NAME-OF,32653,0,1,121, 
123,"DRUG-ID",28103,-1,0„"IDENTIFIER" 
124,"COLLECTED-FOR",33023,0,1,125, 
125"COLLECTED-BY",93,1,1,124, 
126,"CPT4-CODE",24167,-1,0„"IDENTIFIER" 
127,"LOWER-LIMIT-FOR-INPUT",29080,-1,0„"SHORT_STRING" 
128,"UPPER-LIMIT-FOR-INPUT",29080,-1,0„" SHORT STRING" 
129,"LAB-MESSAGE-CODE",35878,-1,0„"IDENTIFIER" 
130,"LAB-MESSAGE-TEXT",35878,-1,0„"LONG_STRING" 
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131,"CPMC-LONG-TEST-NAME",2248,-1,0„"NAME" 
132,"DRUG-ALERT-CODE",28103,-1,0„"SHORT_STRING" 
133,"HAS-DEFAULT-DISPLAYS",94,0,1,134, 
I34,"DEFAULT-DISPLAY-FOR",40441,1,1,133, 
135,"DISPLAYS-ELEMENTS-OF",40441,1,1,136, 
136,"ELEMENTS-DISPLAYED-BY",94,0,1,135, 
137,"HAS-DISPLAY-PARAMETERS",40441,1,1,138, 
138,1S-DISPLAY-PARAMETER-OF",94,0,1,137, 
139,"HAS-TEST-DISPLAY-CLASS-NAME",94,-1,0„"NAME" 
140," DISPLAY-PARAMETER-ORDER",40441,-1,0„"SHORT_STRING" 
141,"ICD9-NAME",21762,-1,0„"LONG STRING" 
142,"CPMC-RADIOLOGY-CODE",406-49,-1,0„"IDENTIFIER" 
143,"EVENT-COMPONENT-DISPLAY-NAME",30363,-1,0„"NAME" 
144,"QUERY-FILLERS",14870,-I,0„"SHORT_STRING" 
145,"PREVENTIVE-HEALTH-NAME",40044,-1,0„"NAME" 
146,"LAB-ALT-TEST-NAME",2248,-1,0„"NAME" 
147,"LAB-ALT-PROC-NAME",144,-1,0„"NAME" 
148,"HAS-PROC-DISPLAY-CLASS-NAME",94,-1,0„"NAME" 
149,"DEFINED-BY-TEST",22155,0,1,150, 
150,"DEFINES-ABNORMAL-FINDING",93,1,1,149, 
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APPENDIX B 
MED FLAT FILE ABSTRACT 
1,1,"T071" 
1,2,"MEDICAL ENTITY" 
1,4, 
1,5,"ENTITY" 
1,6,"Medical Entity" 
1,7, 
1,8, 
1,50,"" 
1,51,"" 
133,1;"T077" 
133 ,2,"CONCEPTUAL ENTITY" 
133,4,1 
1'3'3,5,"" 
133,6,"Conceptual Entity" 
133,7, 
133,8, 
133,50,"" 
133,51,"" 
118,1,"T170" 
1 11 8,2,INTELLECTUAL PRODUCT" 
118,4,133 
118,5,"" 
11 18,6,"Intellectual Product" 
118,7, 
118,8, 
118,50," 
118,51,"" 
21761,1,"T185" 
21761,2,"CLASSIFICATION" 
21761,4,118 
21761,5,"" 
21761,6,"Classification" 
21761,7, 
21761,8, 
21761,50,"" 
21761,51,"" 
23147,1,"" 
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23147,2,"AMERICAN HOSPITAL FORMULARY SERVICE CLASS" 
23147,4,21761 
23147,5,"" 
23147,6,"American Hospital Formulary Service Class" 
23147,7, 
23147,8, 
23147,50,"" 
23147,51," 
23147,55,"" 
23942,1," 
23942,2,"ANTI-INFECTIVE AGENTS" 
23942,4,23147 
23942,4,41225 
23942,5,"" 
23942,6,"Anti-Infective Agents" 
23942,7, 
23942,8, 
23942,50," 
23942,51," 
23942,55,"080000" 
23942,56,"" 
23942,57," 
23942,58,"" 
23942,59," 
23942,60," 
23942,61,"" 
23942,62,"" 
23942,63," 
23942,64," 
23942,65,"" 
23942,66," 
23947,67," 
23942,68,"" 
23942,69,"" 
23942,72,"" 
23942,74,"" 
23942,75," 
23942,76,"" 
23942,108,30365 
23942,113, 
23947,123," 
23942,132,"
" 
23945,1," 
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23945,2,"ANTIBIOTIC PREPARATIONS" 
23945,4,23942 
23945,5,"" 
23945,6,"Antibiotic Preparations" 
23945,7, 
23945,8, 
23945,50,"" 
23945,51,"" 
23945,55,"081200" 
23945,56," 
23945,57,"" 
23945,58,"" 
23945,59,"" 23945,60,"" 
23945,61"" 
23945,62," 
23945,63,"" 
23945,64,"" 
23945,65," 
23945,66," 
23945,67,"" 
23945,68,"" 
23945,69,"" 
23945,72,"" 23945, 4,
23945,75,"" 
23945,76,"" 
23945,108,30365 
23945,113, 
23945,132,"" 
23946,1," 
23946,2,"AMINOGLYCOSIDE PREPARATIONS" 
23946,4,23945 
23946,4,281.20 
23946,5,"" 
23946,6,"Aminoglycoside Preparations" 
23946,7, 
23946,8, 
23946,50,"" 
23946,51,"" 
23946,55,"081202" 
23946,56,"" 
23946,57,"" 
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23946,58,"" 
23946,59,"" 
23946,60," 
23946,61,"" 
23946,62,"" 
23946,63,"" 
23946,64," 
23946,65,"" 
23946,66,"" 
23946,67,''" 
23946,68,"" 
23946,69,"
" 23946,70,"" 
23946,72,"" 
23946,74,"" 
23946,75," 
23946,76," 
23946,108,30365 
23946,112,30379 
23946,113, 
23946,123,"" 
23946,132,"" 
23954,1," 
23954,2,"MISCELLANEOUS ANTIBIOTICS" 
23954,4,23945 
23954,5,"" 
23954,6,"Miscellaneous Antibiotics" 
23954,7, 
23954,8, 
23954,50," 
23954,51,"" 
23954,55,"081228" 
23954,56,"" 
23954,57,"" 
23954,58,"" 
23954,59,"" 
23954,60," 
23954,61,"" 
23954,62," 
23954,63,"" 
23954,64,"" 
23954,65," 
23954,66,"" 
23954,67," 
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23954,68,"" 
23954,69,"" 9395 ,72
23954,74," 
23954,75," 
23954,76," 
23954,108,30365 
23954,113, 
23954,123," 
23954,132,"" 
24075,1," 
24075,2 "EYE, EAR, NOSE, AND THROAT (EENT) PREPARATIONS" 
24075,4,23147 
24075,4,41225 
24075,5," 
24075,6,"Eye, Ear, Nose, and Throat (Eent) Preparations" 
24075,7, 
24075,8, 
24075,50," 
24075,51," 
24075,55,"520000" 
24075,56,"" 
24075,57," 
24075,58," 
24075,59," 
24075,60," 
24075,61,"" 
24075,62,"" 
24075,63," 
24075,64," 
24075,65," 
24075,66," 
24075,67," 
24075,68," 
24075,69," 
24075,72," 
24075,74," 
24075,75," 
24075,76," 
24075,108,30365 
24075,113, 
24075,123,"" 
24075,132," 
70 
24076,1,"" 
24076,2,"EYE, EAR, NOSE, AND THROAT ANTI-INFECTIVES" 
24076,4,23942 
24076,4,24075 
24076,5," 
24076,6,"Eye, Ear, Nose, and Throat Anti-Infectives" 
24076,7, 
24076,8, 
24076,50," 
24076,51," 
24076,55,"520400" 
24076,56,"" 
24076,57,"" 
24076,58,"" 
24076,59,"" 
24076,60,"" 
24076,61,"" 
24076,62,"" 
24076,63,"" 
24076,64,"" 
24076,65,"" 
24076,66," 
24076,67,"" 
24076,68,"" 
24076,69,"" 
24076,72,"" 
24076,74,"" 
24076,75,"" 
24076,76,"" 
24076,108,30365 
24076,113, 
24076,123,"" 
24076,132,"" 
24077,1," 
24077,2,"EYE, EAR, NOSE, AND THROAT ANTIBIOTICS" 
24077,4,23945 
24077,4,24076 
24077,5,"" 
24077,6,"Eye, Ear, Nose, and Throat Antibiotics" 
24077,7, 
24077,8, 
24077,50,"" 
24077,51"" 
24077,55:520404" 
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24077,56,""  
24077,57,""  
24077,58,""  
24077,59,""  
24077,60,""  
24077,61,""  
24077,62,""  
24077,63,""  
24077,64,""  
24077,65,""  
24077,66,""  
24077,67,""  
24077,68,""  
24077,69,""  
24077,72,""  
24077,74,""  
24077,75,""  
24077,76,""  
24077,108,30365 
24077,113, 
24077,123,""  
24077,132,""  
24104,1,""  
24104,2,"HORMONES AND SYNTHETIC SUBSTITUTES""  
24104,4,23147 
24104,4,41225 
24104,5,""  
24104,6,"1-Iormones and Synthetic Substitutes" 
24104,7, 
24104,8, 
24104,50,""  
24104,51,""  
24104,55,"680000" 
24104,56,""  
24104,57,""  
24104,58,""  
24104,59,""  
24104,60,""  
24104,61,""  
24104,62,""  
24104,63,""  
24104,64,"" 
24104,65,""  
24104,66,""  
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24104,67,"" 
24104,68,"" 
24104,69,"" 
24104,72,"" 
24104,74,"" 
24104,75,"" 
24104,76,"" 
24104,108,30365 
24104,113, 
24104,123,"" 
24104,132,"" 
24105,1,"" 
24105,2,"ADRENAL AGENTS"" 
24105,4,24104 
24105,5,"" 
24105,6,"Adrenal Agents"" 
24105,7, 
24105,8, 
24105,50,"" 
24105,51,"" 
24105,55,"680400"" 
24105,56,"" 
24105,57,"" 
24105,58,"" 
24105,59," 
24105,60,"" 
24105,61,"" 
24105,62,"" 
24105,63,"" 
24105,64,"" 
24105,65,"" 
24105,66,"" 
24105,67,"" 
24105,68,"" 
24105,69,"" 
24105,72,"" 
24105,74,"" 
24105,75,"" 
24105,76,"" 
24105,108,30365 
24105,113, 
24105,123,"" 
24105,132,"" 
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24128,1,"" 
24128,2,"SKIN AND MUCOUS MEMBRANE AGENTS"" 
24128,4,23147 
24128,4,41295 
24128,5,"" 
24128,6,"Skin and Mucous Membrane Agents"" 
94128,7, 
24128,8, 
24128,50,"" 
24128,51,"" 
24128,55,"840000"" 
24128,56,"" 
24128,57,"" 
24128,58,"" 
24128,59,"" 
24128,60,"" 
24128,61,"" 
24128,62,"" 
24128,63,"" 
24128,64,"" 
24128,65,"" 
24128,66,"" 
24128,67,"" 
24128,68,"" 
24128,69,"" 
24128,72,"" 
24128,74,"" 
24128,75"" 
24128,76,"" 
24128,108,30365 
24128,113, 
24128,123,"" 
24128,132,"" 
24135,1,"" 
24135,9,"SKIN AND MUCOUS MEMBRANE ANTI-INFLAMMATORY AGENTS" 
24135,4,24128 
24135,4,28102 
24135,5,"" 
24135,6,"Skin and Mucous Membrane Anti-Inflammatory Agents" 
24135,7, 
24135,8, 
24135,50,"" 
24135,51,"" 
24135,55,"840600"" 
74 
24135,56,"" 
24135,57,"" 
24135,58,"" 
24135,59,"" 
24135,60,"" 
24135,61,"" 
24135,62,"" 
24135,63,"" 
24135,64,"" 
24135,65,"" 
24135,66,"" 
24135,67,"" 
24135,68,"" 
24135,69,"" 
24135,72,"" 
24135,74,"" 
24135,75,"" 
24135,76,"" 
24135,108,30365 
24135,113, 
241.35,123,"" 
24135,132,"" 
28102,1,"" 
28102,2,"ANTI-INFLAMMATORY AGENTS"" 
28102,4,23147 
78102,4,41225 
28102,5,"" 
28102,6,"Anti-Inflammatory Agents"" 
28102,7, 
28102,8, 
28102,50,"" 
28102,51,"" 
28102,55,"" 
28102,56,"" 
28102,57,"" 
28102,58,"" 
28102,59,"" 
28102,60,"" 
28102,61,"" 
28102,62,"" 
28102,63,"" 
28102,64,"" 
28102,65,"" 
28102,66,"" 
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28102,67,"" 
28102,68,"" 
28102,69,"" 
2810,72,"" 
28102,74,"" 
28102,75,"" 
28102,76,"" 
28102,108,30365 
28102,113, 
28102,123"" 
28102,1.32,"" 
28103,1,"" 
28103,2,"PHARMACY ITEMS (DRUGS AND NONDRUGS)" 
28103,4,40654 
28103,4,41152 
28103,5," 
28103,6," Pharmacy Items (Drugs and Nondrugs)" 
28103,7, 
28103,8, 
28103,50,"" 
28103,51,"" 
28103,56,"" 
28103,57,"" 
28103,58,"" 
28103,59,"" 
28103,60,"" 
28103,61,"" 
28103,62,"" 
28103,63,"" 
28103,64,"" 
28103,65,"" 
28103,66,"" 
28103,67,"" 
28103,68,"" 
28103,69,"" 
28103,72,"" 
28103,74,"" 
28103,75,"" 
28103,76,"" 
28103,108,30365 
28103,113, 
28103,123,"" 
28103,132,"" 
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28104,I,"" 
28104,2,"DRUG ENFORCEMENT AGENCY (DEA) CONTROLLED SUBSTANCE 
CATEGORY" 
28104,4,41152 
28104,5,"" 
28104,6,"Drug Enforcement Agency (DEA) Controlled. Substance Category" 
28104,7, 
28104,8, 
28104,50,"" 
28104,51,"" 
28104,73,"" 
28109,1,"" 
28109,2,"DRUG ALLERGY CLASS" 
28109,4,41152 
28109,5,"" 
28109,6,"Drug Allergy Class" 
28109,7, 
28109,8, 
28109,50,"" 
28109,51,"" 
28109,70,"" 
28109,112,30379 
28112,1,"" 
28112,2,"DRUG ALLERGY CLASS: GLUCOCORTICOIDS" 
78112,4,28109 
28112,5,"" 
28112,6,"Drug Allergy Class: Glucocorticoids" 
28112,7, 
28112,8, 
28112,50,"" 
28112,51,"" 
28112,70,"02" 
28112,112,30379 
28120,1,"" 
28120,2,"DRUG ALLERGY CLASS: AMINOGLYCOSIDES" 
28120,4,28109 
28120,5,"" 
28120,6,"Drug Allergy Class: Aminoglycosides" 
28120,7, 
78120,8, 
28120,50,"" 
28120,51,"" 
77 
28120,70,"10" 
28120,112,30379 
28202,1,"" 
28202,2,"CPMC FORMULARY DRUG FORMS" 
28202,4,41152 
28202,5," 
28202,6,"CPMC Formulary Drug Forms" 
28202,7, 
28202,8, 
28202,50,"" 
78,02,51,"" 
,8,02,71,"" 
28308,1"" 
28308,2,"DRUGS DISPENSED BY THE GRAM" 
28308,4,28202 
28308,5,"" 
28308,6,"Drugs Dispensed by the Gram" 
28308,7, 
28308,8, 
28308,50,"" 
28308,51,"" 
28308,71,"GM"" 
28385,1''" 
28385,2,"CPMC DRUG: BACITRACIN OINT 30 GM" 
28385,4,24130 
28385,4,28110 
28385,4,28308 
28385,4,31586 
28385,5,"" 
28385,6,"CPMC Drug: Bacitracin Oint 30 Gm" 
28385,7, 
28385,8, 
28385,50,"" 
28385,51,"" 
28385,55,"840404" 
28385,56,"U" 
28385,57,"500.00" 
28385,58,"BACITRACIN OINT 30 GM" 
28385,59," BACXO" 
28385,60,"00168001131" 
28385,61,"_BACIGUENT" 
28385,62,"BACITRAIN" 
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28385,63,"FOUGERA" 
28385,64,"0" 
28385,65,"3" 
28385,66,"N" 
28385,67,"TOPI" 
28385,68,"Y" 
28385,69,"1" 
28385,70,"00" 
28385,71,"GM" 
28385,72,"0" 
28385,73,"0" 
28385,74,'"Q5 W"' 
28385,75,"31812" 
28385,76,"" 
28385,108,30365 
28385,112,30379 
28385,113,30430 
28385,123,"00000186" 
28385,132,"" 
28602,1,"" 
28602,2,"CPMC DRUG: CORTISPORIN OPTH OINT" 
28602,4,24077 
28602,4,28308 
28602,4,32818 
28602,5,"" 
28602,6,"CPMC Drug: Cortisporin Opth Oint" 
28602,7, 
28602,8, 
28602,50,"" 
28602,51,"" 
28602,55,"520404" 
28602,56,"" 
28602,57,"0.00" 
28602,58,"CORTISPORIN OPTH OINT" 
28602,59,"COROO" 
28602,60,"00081019786" 
28602,61,"CORTISPORIN" 
28602,62,"NEOMYCIN/BACITRACIN/POLY/HC" 
28602,63,"BURROUGHS" 
78602,64,"F" 
28602,65,"3" 
28602,66,"N" 
28602,67,''OPTH" 
28602,68,"Y" 
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28602,69,"0" 
28602,70,"02" 
28602,70,"10" 
28602,71,"GM" 
28602,72,"0" 
28602,73,"0" 
28602,74,"Q6W" 
28602,75,"87269" 
28602,76,"819" 
28602,108,30365 
28602,112,30379 
28602,113,30430 
28602,113,30632 
28602,113,30730 
28602,113,30776 
28602,123,"00000447" 
28602,132,"" 
28604,1,"" 
28604,2,"CPMC DRUG: CORTISPORIN OTIC SOLN 10 ML" 
28604,4,24077 
28604,4,28204 
28604,4,32819 
28604,5,"" 
28604,6,"CPMC Drug: Cortisporin Otic SoIn 10 Ml" 
28604,7, 
28604,8, 
28604,50,"" 
28604,51,"" 
28604,55,"520404" 
28604,56,"" 
28604,57,"0.00" 
28604,58,"CORTISPORIN OTIC SOLN 10 ML" 
28604,59,"COROTA" 
28604,60,"00405616110" 
28604,61,"CORTISPORIN" 
28604,62,"NEOMYCIN SULFATE/POLYMYXIN/HC" 
28604,63,"SCHEIN" 
28604,64,"F" 
28604,65,"3" 
28604,66,"N" 
28604,67,"OTIC" 
28604,68,"Y" 
28604,69,"0" 
28604,70,"02" 
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28604,70,"10" 
28604,71,"ML" 
28604,72,"0" 
28604,73,"0" 
28604,74,"Q8W" 
28604,75,"88370" 
28604,76,"819" 
28604,108,30365 
28604,112,30379 
28604,113,30632 
28604,113,30730 
28604,113,30776 
28604,123"00000449" 
28604,132,"" 
29308,1,"" 
29308,2,"CPMC DRUG: NEOMYCIN 500 MG TAB" 
29308,4,28203 
29308,4,31614 
29308,5," 
29308,6,"CPMC Drug: Neomycin 500 Mg Tab" 
29308,7, 
29308,8, 
29308,50,"" 
29308,51,"" 
29308,55,"081202" 
29308,56,"MG" 
29308,57,"500.00" 
29308,58,"NEOMYCIN 500 MG TAB" 
29308,59,"BNE0500" 
29308,60,"39822031010" 
29308,61,"NEOMYCIN" 
29308,62,"NEOMYCIN" 
29308,63,"PHARMA TEK" 
29308,64,"F" 
29308,65,"1" 
29308,66,"N" 
29308,67,"PO" 
29308,68,"Y" 
29308,69,"0" 
29308,70,"10" 
29308,71,"TAB" 
29308,72,"0" 
29308,73,"0" 
29308,74,"W1F" 
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29308,75,"41072" 
29308,76,"044" 
29308,76,"045" 
29308,76,"048" 
29308,76,"168" 
29308,76,"954" 
29308,108,30365 
29308,112,30379 
2.9308,1.13,30730 
29308,123,"00001400" 
29308,132,"" 
29312,1,"" 
29312,2,"CPMC DRUG: NEOSPORIN GU IRRIGANT 1 ML AMP" 
29312,4,24068 
29312,4,32796 
29312,4,34549 
29312,5,"" 
29312,6,"CPMC Drug: Neosporin Gu Irrigant 1 MI Amp" 
29312,7, 
29312,8, 
29312,50,"" 
29312,51,"" 
29312,55,"403600" 
29312,56,"" 
29312,57,"0.00" 
29312,58,"NEOSPORIN GU IRRIGANT 1 ML AMP" 
29312,59,"NEOGU" 
29312,60,"00081074815" 
29312,61,"NEOSPORIN" 
29312,62,"NEOMYCIN /POLYMYXIN B SO4" 
29312,63,"BURROUGHS" 
29312,64,"F" 
29312,65,"1" 
29312,66,"N" 
29312,67,"IRRI" 
29312,68,"Y" 
29312,69,"0" 
29312,70,"10" 
29312,71,"AMP" 
79317,72,"0" 
29312,73,"0" 
29312,74,"W8F" 
29312,75,"89699" 
29312,76,"819" 
82 
29312,I08,30365 
29312,112,30379 
29312,113,30730 
29312,113,30776 
29312,123,"00001403" 
2.9312,132,"" 
29315,1," 
29315,2,"CPMC DRUG: NEOSPORIN TOPICAL OINT 30 GM" 
29315,4,24130 
293I5,4,28308 
29315,4,328I7 
29315,5,"" 
29315,6,"CPMC Drug: Neosporin Topical Oint 30 Gm" 
293I5,7, 
293I5,8, 
293I5,50,"" 
29315,51,"" 
293I5,55,"840404" 
29315,56,"" 
29315,57,"0.00" 
29315,58,"NEOSPORIN TOPICAL OINT 30 GM" 
293I5,59,"NEOXO" 
29315,60,"00168001231" 
29315,6I,"NEOSPORIN" 
29315,62,"NEOMYCIN/BACITRA/POLYMYXIN" 
29315,63,"E.FOUGERA" 
29315,64,"0" 
29315,65,"3" 
29315,66,"N" 
293I5,67,"TOPI" 
29315,68,"Y" 
29315,69,"0" 
29315,70,"10" 
29315,7I,"GM" 
29315,72,"0" 
29315,73,"0" 
29315,74,"Q5W" 
29315,75,"85459" 
29315,76,"819" 
29315,108,30365 
29315,112,30379 
29315,113,30430 
29315,113,30730 
29315,113,30776 
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29315,123,"00001406" 
29478,1,"" 
29478,2,"CPMC DRUG: POLYMYXIN B SULF 500,000U PWD" 
29478,4,28110 
29478,4,31622 
29478,4,33921 
29478,4,34573 
29478,5,"" 
29478,6,"CPMC Drug: Polymyxin B Sulf 500,000u Pwd" 
29478,7, 
29478,8, 
29478,50,"" 
29478,51,"" 
29478,55,"081228" 
29478,56,"U" 
29478,57,"500000.00" 
29478,58,"POLYMYXIN B SULF 500,000U PWD" 
29478,59,"NAPOL5I" 
29478,60,"00081003510" 
29478,61," AEROSPORIN" 
29478,62,"POLYMYXIN B SULFATE" 
29478,63,"BURROUGHS" 
29478,64,"F" 
29478,65,"I" 
29478,66,"N" 
29478,67,"IM/I" 
29478,68,"N" 
29478,69,"0" 
29478,70,"00" 
29478,7I,"PWD" 
29478,72,"0" 
29478,73,"0" 
29478,74,"WIN" 
29478,75,"41320" 
29478,76,"819" 
29478,108,30365 
29478,1I2,30379 
29478,113,30776 
29478,123,"0000I621" 
29478,132," 
29479,1,"" 
29479,2,"CPMC DRUG: POLYSPORIN OPTH OINT 3.5 GM" 
29479,4,24077 
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29479,4,24130 
29479,4,28110 
29479,4,28308 
29479,4,32794 
29479,5," 
29479,6,"CPMC Drug: Polysporin Opth Oint 3.5 Gm" 
29479,7, 
29479,8, 
29479,50," 
29479,51,"" 
29479,55,"520404" 
29479,56,"" 
29479,57,"0.00" 
29479,58,"POLYSPORIN OPTIC OINT 3.5 GM" 
29479,59,"POLOO" 
29479,60,"02420855555" 
29479,61,"POLYSPORIN" 
29479,62,"BACITRACIN/POLYMYXIN B SULFATE" 
29479,63,"B&L" 
29479,64,"F" 
29479,65,"3" 
29479,66,"N" 
29479,67,"OPTH" 
29479,68,"Y" 
29479,69,"0" 
29479,70,"00" 
29479,71,"GM" 
29479,72,"0" 
29479,73,"0" 
29479,74,"Q6W" 
29479,75,"87589" 
29479,76,"8I9" 
29479,108,30365 
29479,112,30379 
29479,113,30430 
29479,113,30776 
79479,123"00001622" 
29479,132,"" 
3I586,1,"" 
31586,2," BACITRACIN PREPARATIONS" 
31586,4,23954 
3I586,4,33921 
31586,5,"" 
31586,6,"Bacitracin Preparations" 
85 
31586,7, 
31586,8, 
31586,50,""  
31586,51,"" 
31586,55,""  
31586,56,"" 
31586,57,"" 
31586,58,"" 
31586,59,""  
31586,60,"" 
31586,61,"" 
31586,62,''BACITRACIN" 
31586,6.3,""  
31586,64,""  
31586,65,"" 
31586,66,"" 
31586,67,"" 
31586,68,""  
31586,69,""  
31586,72,""  
31586,73,"" 
31586,74,"" 
31586,75,""  
31586,76,"" 
31586,108,30365 
31586,113,30430 
31586,123,""  
31586,132,""  
31604,1,"" 
31604,2,"HYDROCORTISONE PREPARATIONS" 
31604,4,28112 
31604,4,33921 
31604,4,34162 
31604,5," 
31604,6," Hydrocortisone Preparations" 
31604,7, 
31604,8, 
31604,50,""  
31604,51,""  
31604,55,"" 
31604,56,""  
31604,57,""  
31604,58,""  
31604,59,""  
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31604,60," 
31604,61,"" 
31604,62,"HYDROCORTISONE" 
31604,62,"HYDROCORTI SONE ACETATE" 
31604,62,"HYDROCORTISONE SOD SUCCINATE" 
31604 ,62,"H YDROCORTISONE CREAM" 
31604,62,"HYDROCORTISONE SODIUM SUCCINAT" 
31604,62," 'HYDROCORTISONE CYPIONATE" 
31604,62,"HYDROCORTISONE VALERATE" 
31604,63,' 
31604,64,''" 
31604,65," 
31604,66,"" 
31604,67," 
31604,68," 
31604,69," 
31604,70," 
31604,72,"" 
31604,73,"" 
31604,74," 
31604,75,1" " 
31604,76,"" 
31604,108,30365 
31604,I12,30379 
31604,I13,30632 
31604,123, 1 " 
31604,132,"" 
31614,1," 
31614,2,"NEOMYCIN PREPARATIONS" 
316I4,4,23946 
31614,4,33921 
31614,5," 
31614,6,"Neomycin Preparations" 
31614,7, 
31614,8, 
3161.4,50," 
316IL1,5I," 
31614,55," 
31614,56,""  
31614,57,""  
31614,58," 
31614,59,"" 
31614,60," 
31614,61," 
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31614,62,"NEOMYCIN" 
31614,62,"NEOMYCIN SULFATE" 141 3," 
31614,64,"" 31614,65," 
31614,66,"" 
31614,67,"" 
31614,68,"" 
31614,69," 
31614,70," 1614,72," 
3161.4,73,"" 
3161.4,74," 
31614,75," 
31614,76," 
31614,108,30365 
316I4,112,30379 
31614,113,30730 
31614,123,"" 
31614,132," 
31622,1" 
31622,2,"POLYMYXIN B PREPARATIONS" 
31622,4,23954 
31622,5,"" 
31622,6,"Polymyxin B Preparations" 
31622,7, 
31622,8, 
31622,50," 
31622,51,"" 
31622,55,"" 
31622,56,"" 
31622,57,"" 
31622,58,"" 
31622,59,"" 
31622,60," 
31622,61," 
31622,62,"POLYMYXIN B SULFATE" 
31622,63," 
31622,64,"" 
31622,65," 
31622,66,"" 
31622,67,"" 
31622,68," 
31622,69,"" 
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31622,72,"" 
31622,74,"" 
3107,75," 
31622,76,"" 
31622,108,30365 
31622,113,30776 
31697,123," 
31677,132," 
32794,1" 
32794,2,"BACITRACIN / POLYMYXIN B COMBINATION PREPARATIONS" 
32794,4,31586 
32794,4,31622 
32794,5,'" 
32794,6,"Bacitracin / Polymyxin B Combination Preparations" 
32794,7, 
32794,8, 
32794,50,"" 
32794,51,"1 " 
32794,55," 
32794,56,""  
32794,57,11 " 
32794,58,"" 
32794,59,"" 
32794,60," 
32794,61,"" 
32794,62,"BACITRACIN/POLYMYXIN B SULFATE" 
:32794,63," 
32794,64,"" 
32794,65,"" 
32794,66,"" 
32794,67,"" 
32794,68,"" 
32794,69," 
32794,72,"" 
32794,73," 
32794,74,"" 
32794,75," 
32794,76,"" 
32794,108,30365 
32794,113,30430 
32794,113,30776 
32794,123," 
32794,132," 
89 
32796,1,"" 
32796,2,"NEOMYCIN / POLYMYXIN B COMBINATION PREPARATIONS" 
32796,4,31614 
32796,4,31622 
32796,5,"" 
32796,6,"Neomycin / Polymyxin B Combination Preparations" 
32796,7, 
32796,8, 
32796,50,"" 
32796,51,"" 
32796,55,"" 
32796,56,"" 
32796,57,"" 
32796,58,"" 
32796,59,"" 
32796,60,"" 
32796,61,"" 
32796,62,"NEOMYCIN /POLYMYXIN B SO4" 
32796,63,"" 
32796,64,"" 
32796,65,"" 
32796,66,"" 
32796,67,"" 
32796,68,"" 
32796,69,"" 
32796,70,"" 
32796,72,"" 
32796,73,"" 
32796,74,"" 
32796,75,"" 
32796,76,"" 
32796,108,30365 
32796,112,30379 
32796,113,30730 
32796,113,30776 
32796,123,"" 
32796,132,"" 
32817,1,"" 
328172,"BACITRACIN / NEOMYCIN / POLYMYXIN B COMBINATION 
PREPARATIONS" 
32817,4,32794 
32817,4,32796 
32817,5," 
32817,6,"Bacitracin / Neomycin / Polymyxin B Combination Preparations" 
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32817,7, 
32817,8, 
32817,50," 
32817,51,"
' 
32817,55,"" 
32817,56,"" 
32817,57,""  
32817,58,""  
32817,59,1" " 
32817,60,"" 
32817,61,"" 
328I7,62,"NEOMYCIN/BACITRA/POLYMYXIN" 
328I7,62,"NEOMYCIN/BACITRACIN/POLYMYXIN" 
32817,63,"" 
32817,64,"" 
32817,65," 
32817,66," 
328I7,67,"" 
32817,68,"" 
32817,69,"" 
32817,70," 
32817,72," 
328I7,73,"" 
32817,74,"" 
32817,75,"" 
32817,76,"" 
32817,108,30365 
32817,112,30379 
32817,11.3,30430 32817,11 7
32817,113,30776 
32817,123,"" 
32817,132,"" 
32818,1,"" 
32818,2,"BACITRACIN / HYDROCORTISONE / NEOMYCIN / POLYMYXIN B 
COMBINATION PREPARATIONS" 
32818,4,32817 
32818,4,32819 
32818,5,"" 
32818,6,"Bacitracin / Hydrocortisone / Neomycin / Polyrnyxin B Combination. 
Preparations" 
32818,7, 
32818,8, 
32818,50," 
32818,51,"" 
32818,55,"" 
32818,56," 
32818,57," 
32818,58,"" 
32818,59,"" 
32818,60," 
32818,61,"" 
32818,62,"NEOMYCIN/BACITRACIN/POLY/HC" 
32818,63," 
32818,64,"" 
32818,65,"" 
32818,66,"" 
32818,67,"" 
32818,68," 
32818,69," 
32818,70," 
32818,72,"" 
32818,73,"" 
32818,74,"" 
3281.8,75,"" 
32818,76,"" 
32818,108,30365 
32818,112,30379 
32818,113,30430 
32818,113,30632 
32818,113,30730 
32818,113,30776 
32818,123,"" 
32818,132," 
32819,1,"" 
32819,2,"HYDROCORTISONE / NEOMYCIN / POLYMYXIN 13 COMBINATION 
PREPARATIONS" 
32819,4,32796 
32819,4,35265 
32819,5,"" 
32819,6,"Hydrocortisone / Neomycin / Polymyxin 13 Combination Preparations" 
32819,7, 
32819,8, 
32819,50,"" 
32819,51,"" 
32819,55,"" 
32819,56,"" 
32819,57,"" 
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32819,58,"" 
32819,59,"" 
32819,60," 
32819,61,"" 
32819,62,"NEOMYCIN SULFATE/POLYMYXIN/HC" 
32819,6:3," 
32819,64," 
32819,65," 
32819,66,"" 
32819,67,1" 
32819,68,1" 
32819,69,"" 
32819,70," 
32819,72,"" 
32819,73," 
32819,74,"" 
32819,75,"" 
328I9,76," 
32819,I08,30365 
32819,112,30379 
32819,113,30632 
32819,113,30730 
32819,113,30776 
32819,123,"" 
32819,132," 
:33921,1," 
33921,2,"DRUG ENFORCEMENT AGENCY (DEA) CLASS 0 - DRUG WITHOUT 
ABUSE POTENTIAL" 
33921,4,28104 
33921,5,"" 
33921,6,"Drug Enforcement Agency (DEA) Class 0 - Drug without Abuse Potential" 
3_3921,7, 
3'3921,8, 
33921,50,F " " 
33921,51," 
3392I,73,"0" 
34162,1," 
34162,2,"GLUCOCORTICOID AGENTS" 
34162,4,24105 
34162,4,28102 
34162,5,e" 
34162,6,"Glucocorticoid Agents" 
34162,7, 
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34162,8, 
34162,50," 
34162,51,"" 
34162,55,"" 
34162,56,"" 
34162,57,"" 
34162,58," " 
34162,59,"" 
34162,60," 
34162,61,"" 
34162,62,"" 
34162,63,"" 
34162,64,"" 
34162,65," 
34162,66," 
34162,67,"" 
34162,68," 
34162,69,"" 
34162,72,"" 
34162,74,"" 
34162,75,"" 
34162,76,"" 
34162,108,30365 
34162,113, 
34162,123," 
34162,132,"" 
35265,1,"" 
35265,2,"TOPICAL HYDROCORTISONE PREPARATIONS" 
35265,4,24135 
35265,4,31604 
35265,5,"" 
35265,6,"Topical Hydrocortisone Preparations" 
35265,7, 
35265,8, 
35265,50," 
35265,51,"" 
35265,55," 
35265,56,"" 
35265,57,"" 
35265,58,"" 
35265,59,"" 
35265,60," 
35265,61," 
35265,62,"" 
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35265,63,"" 
35265,64,"" 
35265,65,"" 
35265,66,"" 
35265,67,"" 
35265,68,"" 
35265,69,"" 
35265,70," 
35265,72," 
35265,73,"" 
35265,74,"" 
35265,75,"" 
35265,76,"" 
35265,108,30365 
35265,1I2,30379 
35265,113,30632 
35265,123," 
35265,132," 
40654,1,"" 
40654,2,"ORDERABLE ENTITY" 
40654,4,133 
40654,5,"" 
40654,6,"Orderable Entity" 
40654,7, 
40654,8, 
40654,50,"" 
40654,51,"" 
41152,1,"" 
41152,2,"PHARMACY CONCEPTS" 
4I152,4,21761 
4I152,5,"" 
41152,6,"Pharmacy Concepts" 
41152,7, 
41152,8, 
41152,50," 
41152,51," 
41225,1,"" 
41225,2,"CPMC FORMULARY DRUG ITEM" 
41225,4,28103 
41125,5," 
41225,6,"CPMC Formulary Drug Item" 
41225,7, 
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41225,8, 41 25,50," 
41225,51," 
41225,56,"" 
41225,57,"" 
41225,58,"" 
41225,59," 
41225,60,"" 
41225,61,"" 
41225,62,"" 
41225,63," 
41225,64," 
41225,65,"" 
41225,66,"" 
41225,67,"" 
41225,68" 
41225,69"" 
41225,72 ," 
41225,74," 
41225,75,"" 
41225,76," 
41225,108,30365 
41225,113, 
41225,123," 
41225,132," 
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